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Abstract
Meta-analysis combines results from several independent studies. Dierent
methods are available to carry out meta-analyses for binary and continuous
outcomes. The eect measures used for binary outcomes are odds ratio (OR),
relative risk (RR), risk dierence (RD), arcsine dierence (AS), hazard ratio
(HR) etc. For continuous outcomes mean dierence (MD) and standardised
mean dierence (SMD) are used in meta-analysis. However, there are many
medical and health studies in which the outcome variables are measured on an
ordinal categorical scale with more than two categories. These categories are
non-numerically valued, usually levels. In a typical ordinal categorical data
there may be L categories C1; C2; : : : ; CL (C1 is the best and CL the worst or
vice versa) and J comparison groups G1; G2; : : : ; GJ . Hence the count data
for such studies are represented by a J  L contingency table. As a special
case when there are two comparison groups in randomised controlled trials
(RCTs), we set a 2  L contingency table. As a result, the ordinary OR,
log OR or RR can not be used directly without splitting the 2  L (L > 2)
contingency table into 2 2 tables.
Among other eect measures for ordinal data there are local and global
odds ratios (Dale, 1984), cumulative odds ratios, continuation odds ratio
(Agresti, 2010) etc. The local odds ratio measures local association for a
specic outcome category not for the whole study. The global odds ratio is
i
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a measure of ratios of the quadrant probabilities (J = L  4). Whereas in
RCTs there are only two comparison groups (J = 2) namely the treatment
and control groups. The cumulative odds ratios provide a comparison of pairs
of levels of the explanatory variable with respect to their entire conditional
distribution of the dependent variable. As a result, these measures are not
appropriate in meta-analysis with RCTs.
The data from studies with several ordered categories are analysed by
various methods in meta-analysis. Some methods require specic model as-
sumptions while others collapse the 2  L (L > 2) contingency table into
2  2 tables for measuring the eect size. For example, the proportional
odds model (Whitehead et al., 2001) requires a proportionality assumption
and there is no well dened variance estimate of the pooled estimator for the
sample size weight method (Edwardes and Baltzan, 2000) that uses general
odds ratio (ORG) as an eect measure.
Therefore we need a method in meta-analysis that can be used for esti-
mating the eect size without any loss of information by merging categories
and is not restricted to any model assumptions.
We propose generalised odds ratio (GOR) as an eect measure for or-
dinal categorical outcomes in meta-analysis (Agresti, 1980). For condence
intervals (CI) of the individual study eects and meta-analysis we employ
independent multinomial distribution approach. A general xed and a ran-
dom eects models are developed using GOR in meta-analysis for ordinal
categorical outcomes.
Heterogeneity is one of the most problematic aspects in many meta-
analyses. We have demonstrated a method to remedy the problem of het-
erogeneity in meta-analysis for ordinal data. Following Saleh (2006) a quasi-
empirical Bayes method (QEBM) is developed using predicted generalised
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odds ratio (PGOR) for heterogeneous ordinal categorical outcomes. This
method identies the extreme studies and improves the meta-analysis in the
presence of heterogeneity. Three dierent meta-analyses on several studies
with dierent degree of heterogeneity are presented. The rst example is of
individual patients data (IPD) on tacrine trials with Alzheimer's disease, the
second example is of misoprostol trials with insignicant heterogeneity and
the third example is from simulation studies with signicant heterogeneity.
The three examples clearly illustrate detailed implementation process and
usefulness of the proposed method.
We apply and compare GOR with OR as an eect measure for binary
outcomes in meta-analysis. Three alternative methods for combining results
from binary outcomes are presented for meta-analysis. The rst method is
a sample size weight method (Edwardes and Baltzan, 2000) for binary out-
comes using ORG. The other two methods employ GOR as an eect measure
for binary outcomes in meta-analysis. We present results by analysing six
RCTs from meta-analysis of D1 versus D2 gastrectomy for gastric adenocar-
cinoma (Memon et al., 2011).
This study also proposes GOR as an eect measure and presents method
in meta-analysis for latent continuous outcomes. GOR is simple and it has
straightforward interpretation. It can be used for more than two treatment
groups as well. Hence GOR is a very useful eect measure in meta-analysis
not only for multilevel ordinal categorical outcomes but also for binary and
latent continuous outcomes.
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1.1 Background and Motivation
There has been an increasing interest in the development of appropriate
measures to ensure that public policy and decision making are based on
results of reliable research. The evidence based scientic research has been
helping decision makers to determine which interventions are doing good
and which are actually harmful, particularly in the health care area. Meta-
analysis is a statistical technique which concerns with the analysis of the
data extracted from independent studies. It also estimates overall measures
of association or eect size and assesses the sensitivity of the results.
History of meta-analysis goes as early as in the beginning of the 20th cen-
tury when Pearson (1904) developed a statistical technique for making sense
of the divergent results from small studies of the eectiveness of inoculation
against typhoid fever. Statistical techniques were also used for combining
study results in agriculture (Yates and Cochran, 1938) and in the medical
area (Beecher, 1995).
Chalmers et al. (1977) conducted one of the rst meta-analyses in medicine
in the modern era. Then in the mid-1980s meta-analysis started to be used
more frequently when Yusuf et al. (1985) published their meta-analysis of
beta blockers in myocardial infarction.
Dierent methods are available to carry out meta-analyses for binary
and continuous outcomes. The eect measures used for binary outcomes are
odds ratio (OR), relative risk (RR), risk dierence (RD), arcsine dierence
(AS), hazard ratio (HR) etc. For continuous outcomes mean dierence (MD)
and standardised mean dierence (SMD) are widely used in meta-analysis.
However, there are many medical and health studies in which the outcome
variables are measured on an ordinal categorical scale with more than two
categories. These categories are usually levels. For example, study on pain
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relief, dementia, head injury, tonsil size etc are measured on ordinal scales
with more than two outcomes. In a typical ordinal categorical data there
may be L categories C1; C2; : : : ; CL (C1 is the best and CL the worst or vice
versa) and J comparison groups G1; G2; : : : ; GJ . Hence the count data for
such studies are represented in a JL contingency table. As a special case in
randomised controlled trials (RCTs) when there are two comparison groups
(treatment and placebo), a 2 L contingency table is used. As a result, the
ordinary OR, log OR or RR can not be used directly without splitting the
2 L (L > 2) contingency table into a number of 2 2 tables.
Clayton (1974) introduced some odds ratio statistics for the analysis of
ordered categorical data assuming a logit model. Later Clayton (1976) gen-
eralised the estimators for the case in which some observations are subject
to censorship. McCullagh (1977) used paired comparisons on the ordinal
variables.
Dale (1984) introduced the local and global odds ratios for measuring
local and global associations for bivariate ordered responses. Unfortunately,
neither of these can be used in meta-analysis for ordinal categorical data
produced by RCTs, because the local odds ratio measures local relationship
for a specic outcome category not for the whole study and the global odds
ratio is a measure of ratios of the quadrant probabilities that incur loss of
information because of merging quadrant rows and columns.
Among other ordinal measures there are cumulative odds ratios, contin-
uation odds ratio etc (Agresti, 2010). The cumulative odds ratios provide a
comparison of pairs of levels of the explanatory variable with respect to their
entire conditional distribution of the dependent variable. As a result, these
measures are not appropriate in meta-analysis for the data produced by the
RCTs.
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The data from such studies with several categories are analysed by various
methods in meta-analysis. Some methods require a specic model assump-
tion while others collapse the 2  L (L > 2) contingency table into 2  2
tables for measuring the eect size. These methods inherently loss valuable
information due to obvious restrictions. Therefore, we need a method that
can be used for estimating the eect size without any loss of information and
is not restricted to any model assumption. The generalised odds ratio (GOR)
is an eect measure free from the above weaknesses. More importantly, or-
dinal categorical data are naturally in ascending or descending order which
makes GOR more suitable eect measure over its competitors.
There are several methods used for combining ndings from repeated
studies. Hedges and Ingram (1985) demonstrated on various parametric and
non-parametric statistical methods for meta-analysis. Sutton et al. (2000)
presented various methods and discussed dierent important issues for meta-
analysis in medical research. A more recent comprehensive update of meta-
analysis methods and issues are covered in Borenstein et al. (2009). In most
cases, they concentrated on the methodologies and issues for binary out-
comes in meta-analysis. Now-a-days, a general xed (Birge, 1932; Cochran,
1937) and standard random eects models (DerSimonian and Laird, 1986)
are widely used for binary outcomes in meta-analysis. Some other mixed
eects models and Bayesian methods are potential area of research for meta-
analysis.
Recently, there has been a sharp increase in the publication of research
articles on ordinal categorical data. Many authors have published books
on methods for ordinal categorical data analysis. Researchers of diverse
disciplines such as sociology, education, public health and wildlife ecology
are using these methods frequently. However, meta-analysis with ordinal
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categorical outcomes has not been paid much attention so far.
Edwardes and Baltzan (2000) proposed pooling 's ( is also known as
Goodman and Kruskal's ) instead of general odds ratio (ORG = (1+)=(1 
)) using sample size weights. This method is useful to calculate the pooled
eect when the individual variance estimates are not provided. However,
a well dened variance estimate for the pooled eect is unavailable under
this method. As a result, we can not nd the CI for pooled ORG for meta-
analysis.
Whitehead et al. (2001) developed a proportional odds model on individ-
ual patient data (IPD) using the log odds ratio with a general framework for
xed and random eects models. However, this method needs a `proportional
odds' assumption for computing the eect measures.
1.2 Generalised Odds Ratio (GOR)
In this study, we attempt to measure the eect size for the 2  L table as
a whole without any loss of information or under any model assumption in
meta-analysis with RCTs. We propose using GOR (Agresti, 1980) as an eect
measure for ordinal categorical outcomes. These outcomes are naturally in
an ascending or descending order which makes GOR suitable as an eect
measure for these outcomes. We also develop a new meta-analysis method
for ordinal categorical outcomes under both the xed and random eects
models. An application is presented using the individual patients data (IPD)
of ve RCTs of anti-cholinesterase drug tacrine in patients with Alzheimer's
disease (Whitehead et al., 2001) and compared with other methods.
Issues of heterogeneity are addressed by computing the value of the chi-
square test (Cochran, 1954) and I2 statistic (Higgins and Thompson, 2002).
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Funnel plots are used to check the publication bias.
Heterogeneity is one of the most common issues of meta-analysis. Use
of random eects model is not always a cure (cf. Shuster, 2010; Doi SA et
al., 2011). To deal with this issue with ordinal categorical outcomes a quasi-
empirical Bayes method (QEBM) (cf. Saleh, 2006, p.157) is developed using
GOR. This method demonstrates a remedy to the problem of heterogeneity
in meta-analysis for ordinal data. This method identies the extreme studies
and improves the meta-analysis in terms of better statistical agreement in
the presence of heterogeneity.
Three dierent meta-analyses on several studies with dierent degree of
heterogeneity are presented. The rst example is of IPD of tacrine trials
with insignicant heterogeneity, the second example is of misoprostol trials
with moderately insignicant heterogeneity and the third example is from
simulation studies with signicant heterogeneity. The three examples clearly
illustrate detailed implementation process and usefulness of the proposed
method.
We apply and compare GOR as an eect measure for binary outcomes
with OR and ORG in meta-analysis. Three alternative methods are also pre-
sented for combining estimates from binary outcomes. The rst method is
the sample size weight method adopted from Edwardes and Baltzan, (2000).
The other two methods use GOR as an eect measure and independent bi-
nomial distribution approach for estimating the variance for individual study
and meta-analysis. We present results by analysing six RCTs from a meta-
analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma (Memon et
al., 2011).
This study also shows GOR as an eective outcome measure and presents
methods in meta-analysis for latent continuous outcomes. The concept of
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GOR is straightforward and it has mathematically amenable variance es-
timates for both individual study and meta-analysis. It can be well used
for more than two treatment groups as well. These properties make GOR
a useful outcome measure in meta-analysis not only for multilevel ordinal
categorical outcomes but also for binary and latent continuous outcomes.
1.3 Contribution
Main contributions of this thesis are as follows:
 Propose GOR as an eect measure for ordinal categorical outcomes
for data produced by RCTs and apply it in meta-analysis. The GOR
has never been used as an eect measure in meta-analysis. Employing
GOR as an eect measure for multilevel ordinal categorical outcomes
we can estimate the eect size without any loss of information or un-
der the restriction of model assumption or merging multilevel outcome
categories into dichotomies.
 Develop general xed and a random eects models using GOR for ordi-
nal categorical outcomes under independent multinomial distribution.
 Propose a quasi-empirical Bayes method (QEBM) using GOR for het-
erogeneous ordinal categorical outcomes in meta-analysis.
 Apply and compare GOR as an eect measure with OR for binary
outcomes and derive a general xed and random eects model using
GOR for binary outcomes.
 Use GOR for continuous or latent continuous outcomes in meta-analysis.
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 Write computer programs (R-codes) for all computations and plotting
in this thesis.
1.4 Thesis Outlines
The remaining chapters of the thesis are organised as below. Chapter 2
reviews some eect measures and meta-analysis methods used for ordinal
categorical outcomes. This covers a new meta-analysis method using GOR
for ordered categorical outcomes under both xed and random eects models.
A QEBM is presented using GOR for heterogeneous ordinal categori-
cal outcomes in Chapter 3. Here the predicted GOR is used for improved
meta-analysis in the presence of heterogeneity. We generate ten heteroge-
neous studies by simulation using multinomial distribution as there are no
signicant heterogeneous studies available for ordinal categorical outcomes.
Chapter 4 contains a comparison of meta-analysis methods for binary out-
comes. This chapter derives a meta-analysis method using GOR for binary
outcomes under general xed and random eects models and then compare
with the existing methods currently in use.
Chapter 5 deals with the continuous outcomes in meta-analysis.
In Chapter 6, we rap up by summarising the main concepts proposed and
results found in this thesis.
The three appendices contain some related additional topics, R-codes
used for computations in the main four chapters and list of publications.
Chapter 2
Methods for Ordinal
Categorical Data
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2.1 Introduction
There are many medical and biological studies in which the response variables
are measured on an ordinal categorical scale. Often these outcome categories
are more than two. As a result, the ordinary odds ratio (OR) or log odds
ratio (LOR) can not be used directly without splitting the J  L (J > 2,
L > 2) contingency table into 2 2 tables. Clayton (1974) introduced some
odds ratio statistics for the analysis of ordered categorical data assuming a
logit model. Clayton (1976) generalised the estimators for the case in which
some observations are subject to censorship. McCullagh (1977) used paired
comparisons on the ordinal variables.
Dale (1984) introduced the local and global odds ratios for measuring local
and global associations for bivariate ordered responses. However, neither of
these can be used in meta-analysis for ordinal categorical data produced by
RCTs. Because the local odds ratio measures only the local relationship for
a specic outcome category not for the whole study and the global odds ratio
incurs loss of information by merging categories.
Edwardes and Baltzan (2000) proposed pooling 's (also known as Good-
man and Kruskal's ) instead of general odds ratio (ORG = (1+ )=(1  ))
using sample size weights. This method is useful to calculate individual study
eect and associated condence intervals (CI). However, a well dened vari-
ance estimate for the pooled eect is unavailable and hence no CI can be
found under this method.
Whitehead et al. (2001) developed a proportional odds model on indi-
vidual patient data using the LOR with a general framework for xed and
random eects models. However, this method needs a `proportional odds'
assumption for computing the eect measures.
To overcome these issues, we propose GOR (Agresti, 1980) in meta-
CHAPTER 2. METHODS FOR ORDINAL CATEGORICAL DATA 11
analysis as an eect measure for ordinal categorical outcomes. There are
several advantages of GOR over other eect measures. The GOR has simple
and straightforward interpretation and can be used for continuous outcomes
in meta-analysis. The GOR can also be used with multiple treatment groups
for ordinal categorical outcomes. For binary outcomes with two comparison
groups GOR reduces to ordinary OR. So GOR is a universal eect measure in
meta-analysis and is applicable for binary, ordinal and continuous outcomes.
The rest of this chapter is organised as follows. Section 2:2 reviews the
eect measures and methods usually used in meta-analysis for ordinal cat-
egorical outcomes. Section 2:3 presents the proposed meta-analysis method
using GOR for ordinal categorical outcomes. Section 2:4 contains application
of an individual patient data set. Finally, a chapter summary is presented in
Section 2:5.
2.2 Review
In this section we review the eect measures and important methods normally
used for ordinal data in meta-analysis.
2.2.1 Eect Measures
There are some indices that are used for measuring the eect size in meta-
analysis with ordinal categorical outcomes. Some of these measures are dis-
cussed below.
(a) Odds Ratio (Corneld, 1951; Edwards, 1963; Mosteller, 1968)
The odds ratio (OR) is one of the most frequently used indices in
epidemiology and meta-analysis. The OR can be calculated from the
CHAPTER 2. METHODS FOR ORDINAL CATEGORICAL DATA 12
Table 2.1: Data of a single RCT
Intervention Failure/Dead Success/Alive
New treatment a b
Control c d
data (see Table 2:1) as
OR =
a=c
b=d
=
odds of treated in failure
odds of treated in success
=
a d
b c : (2.1)
In a RCT setting for an undesirable outcome OR < 1 indicates an im-
provement on the new treatment, OR > 1 indicates the new treatment
is not eective, and OR = 1 indicates the two comparison groups are
very comparable. The converse is true for desirable outcomes. The cell
with zero frequency is analysed adding 1
2
to each entry before calcula-
tion of OR for 2 2 tables.
Despite its frequent use with binary outcomes in meta-analysis, it can
not be directly used as an eect measure for more than two outcome
categories.
(b) Local Odds Ratio (Dale, 1984)
The data for RCT with ordinal categorical outcomes can be presented
in a 2 L contingency table. Then the local odds ratio is dened as
	l =
lj1(l+1)j2
lj2(l+1)j1
; l = 1; : : : ; L  1: (2.2)
Local odds ratio measures the association between the row variable with
the preferred category in the column variable in a 2  L contingency
table.
(c) Global Odds Ratio (Dale, 1984)
Global odds ratio is dened as the odds ratio of a (2 2) contingency
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table when the adjacent rows and columns of a (JL) contingency table
is collapsed into a 22 table. That is, a global odds ratio is a function
of the quadrant probabilities of the original (JL) contingency table .
A (J L) table has (J   1)(L  1) ways of merging rows and columns
into 2 2 table.
The global cross ratio 	jl may be expressed as an odds ratio of cumu-
lative events:
	jl = odds(Z1  jjZ2  l)=odds(Z1  jjZ2 > l) (2.3)
= odds(Z2  ljZ1  j)=odds(Z2  ljZ1 > j): (2.4)
(d) Cumulative Odds Ratio (Agresti, 2010, p.18)
The cumulative odds ratios use the sample conditional cumulative dis-
tribution functions of Y given x as
^Cjl =
F^ljj=(1  Fljj)
F^ljj+1=(1  F^ljj+1)
: (2.5)
These odds ratios are natural when x is an explanatory variable. They
provide a comparison of pairs of levels of x with respect to their entire
conditional distribution on Y . For a 2L tables, global and cumulative
odds ratios are identical. These (local, global and cumulative) odds
ratios are the regular odds ratios computed for the 22 tables obtained
by collapsing the row and column classications into dichotomies. As
a result, none of these can be used as an eect measure for the whole
table 2 L or J  L as in meta-analysis.
(e) General Odds Ratio (Edwardes and Baltzan, 2000)
Edwardes and Baltzan proposed the general odds ratio (ORG) for JL
tables as
ORG =
1 + 
1   ; (2.6)
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where  = (P  Q)=(P +Q), is also known as Goodman and Kruskal's
, P =
P
j<j0
P
l<l0 njlnj0l0 and Q =
P
j<j0
P
l>l0 njlnj0l0 considering njl
be the number of observations with exposure j and severity l. It is
important that the authors showed after few simple algebraic manipu-
lation ORG = P=Q, which is exactly the same as Agresti's  (Agresti,
1980).
2.2.2 Issues of Meta-Analysis
Two of the most common issues of meta-analysis are heterogeneity and pub-
lication bias. We discuss these issues here briey.
Heterogeneity
Heterogeneity refers to the between study eect size variation. Random ef-
fects model accounts for heterogeneity to an extent but they do not explain
why the study results vary. Subgroup analysis and regression methods can
be used to identify the associations between study or patient characteristics
and the outcome measures in meta-analysis of RCTs. It has now become
common practice reporting Q statistic (Cochran, 1954) with associated de-
grees of freedom (df) and p-value for identifying heterogeneity and I2 statistic
(Higgins and Thompson, 2002) for quantifying heterogeneity.
Graphically heterogeneity can be explored using plot of normalised (Z)
scores, forest plot, radial plot (Galbraith, 1988) and L'Abbe plot (L'Abbe et
al, 1987). Among these graphical tests, plot of Z scores and forest plot are
now widely used for meta-analysis data representation.
 Plot of normalised (Z) scores: The Z-scores or standardised residuals
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for each study can be calculated by
Zi =
 i    
se( i)
; (2.7)
where  i is the observed eect size estimate from the ith study,   is
the weighted average of these eect sizes, that is,   =
Pk
i !i i=
Pk
i !i,
where !i = is the weight for the ith study and se( i) = 1=!i =q
var( i). Under the null hypothesis that all the eect sizes are equal,
the distribution of these Z-scores should be normal with mean zero and
variance one. Large absolute Z values indicate signicant deviations of
individual study eect from the pooled or average eect (Greenland,
1987).
 Forest plot: A forest plot is a graphical display of representing the re-
sults of a meta-analysis. This plot is usually drawn using the eect
estimate on a natural logarithmic scale along with their 95% CIs. A
vertical line at the pooled eect estimate representing the meta-analysis
estimate and a vertical line representing no eect are also drawn. Some-
times a body of text consisting of study names, publication years, eect
estimates and CI values are also included. The forest plot was named
after a breast cancer researcher Pat Forrest and hence sometimes spelt
`forrest plot' (Lewis and Clarke, 2001).
Q statistic
A very common statistical test, the Cochran's (1954) Q test examines the
existence of homogeneity (heterogeneity) citing a p-value. This is dened as
Q =
kX
i=1
!i( ^i    )2; (2.8)
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where  ^i = Treatment eect estimate in the ith study, k = number of studies
combined,   =
P
i
!i ^iP
i
!i
is the weighted estimator of treatment eect and !i
is the attached weight (inversely proportional to the conditional variance) of
the ith study in the meta-analysis.
The following computation friendly form is available
Q =
kX
i=1
!i ^
2
i  
(
Pk
i=1 !i ^i)
2Pk
i=1 !i
 2k 1 (2.9)
under H0 :  1 =  2 =;    ;=  k =  0. For homogeneous studies the null hy-
pothesis is not rejected which does not indicate statistical signicance to use
the common value whether the treatment is in favour or not. However, Fleiss
(1986) recommended using a cut-o signicance level of 0:10 rather than the
usual 0:05. This test is of low in power with few studies and excessive power
with many studies.
I2 statistic
The I2 statistic introduced by Higgins and Thompson (2002) is dened as
I2 =
Q  df
Q
 100%; (2.10)
and represents the proportion of total variation in the estimates of treatment
eect that is due to heterogeneity between studies. The I2 statistic can also
be expressed in the form
I2 =
Between variance
Total variance
 100% = ^
2
s2W + ^
2
; (2.11)
that is, the ratio of between variance to total variance across the observed
eect estimates. The important aspects of this statistic are that it is easily
interpretable and does not depend on the number of studies or type of out-
come variable.
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Subgroup Analysis
Subgroup analysis can be carried out in meta-analysis by investigating sub-
sets of studies or patient characteristics. One can also analyse the subsets
of patients being pooled. There are three computational (Borenstein et al.,
2009) models available such as xed eect, random eects using separate
estimates of  2 and random eects using pooled estimate of  2. Three meth-
ods namely, Z-test, a Q-test based on analysis of variance and a Q-test for
heterogeneity can be used for comparing the subgroups.
If it is assumed that the between variation is the same within all sub-
groups, a pooled estimate can be calculated. If the between variation does
dier from one subgroup to the next, then we would estimate  2 within sub-
groups and use separate estimate of  2 for each subgroup. Although when
there are a few studies within subgroups, it may be preferable to pool the
estimates.
Regression models for meta-analysis
Regression models can also be used under xed eects model (meta-regression
model) (Hedges, 1994) and random eects model (mixed eects model) for
exploring heterogeneity. However, regression models are mostly useful when
the number of studies is large (Raudenbush, 1994).
Publication Bias
It is a well known fact that research with statistically signicant results
is more likely to be published or published more quickly than work with
insignicant results. This leads to a dominance of false positive results in
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the literature. This is known as publication bias. The implications of this
for meta-analysis are that combining only the identied published studies.
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Figure 2.1: Funnel plot indicating absence of publication bias
It is now a common practice to report presence or absence of publica-
tion bias and to assess the eects of publication bias in meta-analysis. The
following tools can be used for identifying publication bias.
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Figure 2.2: Funnel plot showing presence of publication bias
 The funnel plot
 Rank correlation test (Begg and Mazumdar, 1994)
 Linear regression test (Egger et al, 1997)
 Trim and ll method (Duval and Tweedie, 2000)
The funnel plot is now widely used reporting publication bias in meta-
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analysis. Therefore, we will only discuss funnel plot here briey.
The funnel plot
The treatment eects from individual studies are usually plotted against their
standard errors (se) (or inverse of the se) instead of the corresponding sample
sizes. A plot of inverse of se versus logarithm of the treatment eect from
individual studies in a meta-analysis should thus be shaped like a funnel if
there is no publication bias (Light and Pillemar, 1984).
However, plotting treatment eects against standard errors instead of
against the inverse of standard errors are not the same. The visual impression
may be dierent in those situations. To detect publication bias by a funnel
plot there needs to be a range of studies with varying eect sizes. It is
also possible that an asymmetric funnel plot may be caused by factors other
than publication bias, such as quality of studies, intervention, dierences
in underlying risk, poor design of small studies, choice of eect measure,
inadequate analysis, chance and number of studies (Egger et al, 1997).
2.2.3 Proportional Odds Model
Whitehead et al. (2001) used the proportional odds model in meta-analysis
for ordinal outcome categories using individual patient data (IPD). To il-
lustrate this method, let there be k independent studies each comparing a
treatment with a control. Each patient has a response which falls into one
of the L ordered categories C1; : : : ; CL; (L > 2) such that C1 is the best and
CL the worst. Suppose that there are ni patients in the ith study and n
=
Pk
i=1 ni is the total number of patients in all of the studies combined. Let
ijr be the probability that the jth subject in the ith study has a response
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in category Cr. Again consider Qijr to be the associated probability of a
response in category Cr or better, so that Qijr= ij1+ ij2+ : : :+ ijr and
QijL=1. Then the proportional odds model is dened by
ijr = log
 
Qijr
1 Qijr
!
= r + ij; r = 1; : : : ; L  1; (2.12)
where r is the rth intercept and ij=1x1ij+ : : :+qxqij is a linear combina-
tion of explanatory variables. This model assumes `proportional odds' that
the log odds ratio associated with a unit increase in the explanatory variable
does not depend on the intercept. Whitehead et al. (2001) also developed
several meta-analysis methods for ordinal outcomes using IPD under xed
and random eects models.
2.2.4 Sample Size Weight Method
Edwardes and Baltzan (2000) proposed a meta-analysis method by pooling
 (where  = (P   Q)=(P + Q)) is also known as Goodman and Kruskal's
, P =
P
j<j0
P
l<l0 njlnj0l0 and Q =
P
j<j0
P
l>l0 njlnj0l0 considering njl be the
number of observations with exposure j and severity l) instead of pooling
general odds ratio, ORG = (1+)=(1 ), using sample size weight to avoid
data change (Agresti, 1980; Goodman and Kruskal, 1972). They proposed
weighting each i by
TNi =
0@X
i<j
ninj
1A2 =X
i<j
(ni + nj)ninj: (2.13)
As a special case when J = 2, then TN =n1n2=(n1 + n2). The sample size
weighted mean eect is given as
 =
X
i
TNii=
X
i
TNi (2.14)
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and the pooled ORG is calculated as ORG=(1 + )=(1   ). Condence
intervals (CI) for pooled ORG may be formed using
SE() =
 X
i
T 2NiSE(i)
2
!1=2
=
X
i
TNi: (2.15)
The standard error estimate SE(ORG) is derived from Goodman and Kruskal's
general formula (Goodman and Kruskal, 1972) as
SE(ORG) =
1
Q
24X
i
X
j
nijR
2
ij
351=2 ; (2.16)
where Rij = ORG(Bij +Cij) Aij  Dij, n+j =
P
i nij, Aij =
P
s<i
P
t<j nst,
Bij =
P
s<i
P
t>j nst, Cij =
P
s>i
P
t<j nst, Dij =
P
s>i
P
t>j nst.
An asymptotic standard error of log(ORG) is estimated by
SE(logORG) = 2 SE()=(1  )2 (2.17)
and a 95% CI for ORG is
fORG exp[ 3:92SE()=(1 2)];ORG exp[3:92SE()=(1 2)]g; (2.18)
where exp() is the exponential function, and 3:92 is 2  1:96. The sample
size weight method can be used to estimate the eect size of the studies.
Unfortunately, a well dened variance estimate of the estimated pooled ef-
fect is unavailable for this method. Hence this method can not be used for
constructing CI of meta-analysis.
2.3 Proposed Method: Meta-Analysis using
GOR
2.3.1 GOR
Let J be the number of comparison groups with L ordered outcome categories
in each group. For RCTs with two comparison groups the 2L contingency
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table represents the joint distribution of two ordinal categorical variables:
Table 2.2: Contingency table for the ith study.
Groups Category 1 Category 2    Category L Sample size
Treatment Xi11 Xi12    Xi1L ni1:
Control Xi21 Xi22    Xi2L ni2:
In Table 2:2, Xijl is the count of the lth category in the jth group for
the ith study, nij: is the total count of jth group for the ith study, Xi1L =
ni1: Xi11 Xi12      Xi1(L 1), Xi2L = ni2: Xi21 Xi22      Xi2(L 1).
When L = 2, the GOR reduces to the OR for a single 2  2 contingency
table.
The GOR is dened as the ratio of the proportions of concordant and
discordant pairs (Agresti, 1980) in a contingency table. A pair is said to be
concordant if the subject ranked higher on groups also ranks higher on cate-
gories or vice versa. Without loss of generality we assume that the response
in category l0 is more severe than the response in category l where l < l0.
Mathematically, the GOR for the ith study is dened as
 i = (di)
 1ci; (2.19)
where ci =
PL 1
r=1
PL
s=r+1irj1isj2 and di =
PL
r=2
Pr 1
s=1irj1isj2. Here,
ci denotes the probability that the response of a randomly selected subject
from group 2 (control) is more severe than the response of a randomly selected
subject from group 1 (treatment). Similarly, di denotes the probability that
the response of a randomly selected subject from group 1 is more severe than
the response of a randomly selected subject from group 2. The data with
zero cell count is analysed by adding 1
L
to each entry before calculation of
the GOR. The value of  i may vary from 0 to1.  i = 1, represents identical
comparison groups as it is in the OR.
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Suppose an independent random sample of size nij: is taken from group
j (j = 1; 2) and Xijl denote the count falling into category l of the ith
study. Then the random vector (Xij1; Xij2; : : : ; XijL) follows the multinomial
distribution with parameters nij: and 
0
ij = (i1jj; i2jj; : : : ; iLjj), where
iljj is the probability of a subject to be in the lth category within the jth
comparison group for the ith study.
The maximum likelihood estimator (MLE) of iljj is given by ^iljj =
Xijl=nij: for the ith study. For large nij:,
p
nij:(^ij   ij), where ij 0 =
(i1jj; i2jj; : : : ; iLjj), asymptotically follows a L-dimensional multivariate nor-
mal distribution with mean vector 0 and L  L covariance matrix with the
diagonal entries iljj(1   iljj), and o-diagonal entries  iljjil0jj for l 6= l0.
The MLE of  i, say  ^i, is dened as
 ^i = (^di)
 1^ci; (2.20)
where ^ci =
PL 1
r=1
PL
s=r+1 ^irj1^isj2 and ^di =
PL
r=2
Pr 1
s=1 ^irj1^isj2 for the ith
study.
Next, we present a general xed eects model (FEM) (Birge, 1932) (Cochran,
1937) and standard random eects model (REM) (DerSimonian and Laird,
1986) using GOR for multilevel ordinal outcomes. Consider  ^i to be an es-
timate of the true eect size  i in the ith study as  ^i= i + ei, where ei
is the error with which  ^i estimates  i. In the FEM, var( ^i) = vi, and in
REM var( ^i) = 
2
  +vi, where 
2
  is the random eects variance and vi is the
variance due to sampling error in the ith study. If  2  = 0, the above REM
would reduce to the FEM.
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2.3.2 GOR under Fixed Eects Model
The inverse variance weighted method is most widely used amongst the xed
eects models. For k independent studies if  ^i represents logarithm of GOR
(LGOR) and vi represents the variance of the eect estimator, then assuming
 1 =  2 =;    ; k =  0, a pooled estimate of the treatment eect is given
by
 ^0 =
P
i !i ^iP
i !i
: (2.21)
For an arbitrary number of outcome categories (L) in RCTs in which each
row is modeled as an independent multinomial distribution, the estimated
variance of the ith study is
!^ 1i =
L 1X
l=1
2X
j=1
1
nij:^ijl(1  ^ijl) ; (2.22)
where nij: is the total count of the jth group for the ith study, ^ijl = Xijl=nij:
is the MLE of ijl and Xijl is the count of the lth category in the jth group
for the ith study.
Assuming  ^i's are normally distributed, an approximate 100(1  )% CI
for the ith GOR is given by the formula
exp[ ^i  z=2! 1=2i ]; (2.23)
where z=2 is the 100 =2 percentage point of a standard normal distribu-
tion.
An estimator of the variance of the pooled estimator of  0 is given by
!^ 1 = var( ^0) = 1=
kX
i=1
!i: (2.24)
If  ^0 is assumed to be normally distributed, an approximate 100(1 )% CI
for the population eect,  0, is given by
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exp[ ^0  z=2! 1=2] (2.25)
for the meta analysis.
2.3.3 GOR under Random Eects Model
The standard random eects model (DerSimonian and Laird, 1986) for the
GOR can be introduced as follows: Let ^ 2  be the estimate of the between
study variance. Dene ! and s2W to be the mean and variance of the weights
from the k studies:
! =
kX
i=1
!i=k and s
2
W =
1
k   1
 
kX
i
!2i   k!2
!
: (2.26)
Further, dene
U = (k   1)
 
!   s
2
W
k!
!
and Q =
kX
i=1
!i( ^i    :)2; (2.27)
where Q is the heterogeneity statistic, also known as Cochran's 2 statistic
(Cochran, 1954) for testing the H0 =  1 =  2 =    k =  0. The esti-
mated component of variance due to inter-study variation in eect size, ^ 2 ,
is calculated as
^ 2  =
8><>: 0 if Q  k   1(Q  (k   1))=U if Q > k   1: (2.28)
Then adjusted weights !i for each of the studies can be calculated as
!i =
1
[1=!i] + ^ 2 
: (2.29)
A 100(1  )% CI for  i is given by
exp[ ^iR  z=2=
q
!i ] (2.30)
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under the assumption of normality of  ^iR.
The point estimate for the mean treatment eect of all studies,  0, can
be computed by
 ^0R =
kX
i=1
!i  ^i=
kX
i=1
!i with var( ^0R) = 1=
kX
i=1
!i : (2.31)
If normality of  ^0R is assumed, a 100(1  )% CI for  0 is given by
exp[ ^0R  z=2=
vuut kX
i=1
!i ]: (2.32)
2.4 Application
We consider the IPD of ve RCTs (Table 2:3) of anti-cholinesterase drug
tacrine in patients with Alzheimer's disease (Whitehead et al., 2001) to ap-
ply the proposed method and compare results from dierent methods. The
categories of this trials are made by the Clinical Global Impression of Change
scale (CGIC). The CGIC is based on a seven point scale where 1, 2 and 3
represent `very much improved', `much improved' and `minimally improved'
respectively, 4 indicates `no change', and 5, 6 and 7 represent `minimally
worse', `much worse' and `very much worse' respectively. For the analysis
purpose they combined categories 1 and 2, and 6 and 7 as there were very
few patients in the two extreme categories.
The second last column of Table 2:3 contains the LOR and standard
errors (SE) from proportional odds model. The last column contains the log
GOR and SE from the proposed method. As ORG values are exactly the
same as GORs, those are not included in the table.
Table 2:4 shows the comparison of meta-analysis estimates (in logarithmic
scale) and their associated SEs for the three methods used. The last three
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Table 2.3: Estimate of LOR and LGOR along with SE for tacrine data
Study Groups C1 C2 C3 C4 C5 T LOR(SE) LGOR(SE)
1 Tacrine 4 23 45 22 2 96 0.284 (0.261) 0.248 (1.033)
Placebo 2 22 54 29 3 110
2 Tacrine 14 119 180 54 6 373 0.224 (0.242) 0.197 (1.167)
Placebo 1 22 35 11 3 72
3 Tacrine 13 20 24 10 1 68 0.360 (0.331) 0.299 (0.901)
Placebo 7 16 17 10 3 53
4 Tacrine 21 106 175 62 17 381 0.785 (0.173) 0.659 (0.569)
Placebo 8 24 73 52 13 170
5 Tacrine 3 14 19 3 0 39 0.492 (0.422) 0.434 (1.358)
Placebo 2 13 18 7 1 41
columns of Table 2:4 contain the heterogeneity statistic Q, p-value, and I2
statistic.
Figure 2:3 represents the forest plot of the ve RCTs of tacrine data using
GOR. The horizontal lines represent 95% CIs for the ve studies and meta-
analysis. The pooled estimate at 1:54 is obtained by combining all GORs of
the ve studies using the proposed method.
In the rst meta-analysis of the tacrine trials (Qizilbash et al., 1998)
the OR for improvement on the CGIC scale for patients receiving tacrine
compared with those receiving placebo was reported 1:58 (SE = 0:270).
Meta-analysis using proportional odds model produced the estimated
OR = 1:66 under xed eects model and OR = 1:62 under random ef-
fects model. The heterogeneity statistic Q = 4:86, df = 4, p = 0:30 and
I2 = 17:69% [0%; 99:69%] suggest there exists insignicant heterogeneity
(Whitehead et al., 2001; Higgins and Thompson, 2002).
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Table 2.4: Comparison of meta-analysis estimates for the tacrine data
Methods MA SE Q p-value I2
Proport. odds model 4.86 0.300 17.69%
FEM 0.504 0.112 [0%, 99.69%]
REM 0.481 0.128
Sample size weight 1.60 0.809 0%
FEM 0.426 - [0%, 97.7%]
REM 0.426 -
Proposed method 0.34 0.987 0%
FEM 0.430 0.391 [0%, 89%]
REM 0.430 0.391
Meta-analysis using sample size weight (Edwardes and Baltzan, 2000)
gives the estimated pooled ORG = 1:53. The authors reported that an
advantage to sample size weighting is that the pooled estimate may be based
on studies for which variance is not reported. However, a variance estimate is
required for the CI of pooled ORG. We did not report the estimated variance
for the pooled estimate as there is no well dened variance expression for the
pooled ORG. The authors also did not nd the CI for pooled ORG in their
meta-analysis (Edwardes and Baltzan, 2000). The heterogeneity statistic
Q = 1:60, df = 4, p = 0:809 and I2 = 0% [0%; 97:7%] suggest there exists no
heterogeneity in the data set.
The proposed meta-analysis method using GOR results estimated GOR
= 1:54. The tests of heterogeneity are statistically insignicant Q = 0:341,
df= 4, p = 0:987; and I2 = 0% [0%; 89%].
Although the CI of the pooled eect measure for the proposed method is
wider than the proportional odds model, we believe the true scenario has been
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Figure 2.3: Forest plot of the ve RCTs of tacrine using GOR
depicted by the GOR. Regarding the heterogeneity statistic Q, it is observed
that as the number of categories increases the value of Q decreases. For the
tacrine data, with ve categories Q = 0:43, with three categories Q = 1:83,
and with two categories Q = 4:86. As proportional odds model is using LOR,
it is unreasonably reducing the SE which entails a higher individual weight.
That results the higher Q value for the proportional odds model.
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Figure 2.4: The funnel plot suggests that there is no publication bias
2.5 Summary
The main contribution of this chapter is that we develop a meta-analysis
method using GOR for multi-level ordinal categorical outcomes and com-
pare the results with two existing methods for the tacrine trials data. The
currently available proportional odds model is restricted to the proportion-
ality assumption and there is no well dened variance estimate of the pooled
estimate for the sample size weight method. Use of the LOR or similar eect
measures for multi-level ordinal outcomes by collapsing a 2  L table into
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2  2 tables causes loss of information, inate the estimate and inappropri-
ately reduce the spread.
Here the treatment eect of tacrine over placebo is evident from the meta-
analyses. Of the three meta-analyses the treatment eect produced by the
proportional odds model is the highest. The treatment eects produced by
the other two methods are very close. This also emphasises the point that
use of the proportional odds model may have reduced the SE of the eects
by using LOR.
It is revealed that the use of the proportional odds model actually under-
mines the real variability in the data set of ve outcome categories. This is
caused by the reduction of the ve categories into only two categories which
in turn unreasonably reduce the spread. As a result, the SE for LOR is less
than what it should be with ve categories. Use of the GOR and multino-
mial distribution can produce the true variance taking into account all the
outcome categories in a data set.
It is also observed that the majority of patients from the ve tacrine
trials fall in the middle three categories. As a result, the eect measure
in proportional odds model may be inated because of the proportionality
assumption.
The proposed meta-analysis method using GOR is very simple and has
straightforward interpretation. It has simple variance estimate for individual
study and meta-analysis. It can also be used for binary and latent continuous
outcomes (see Chapter 4 and Chapter 5). Moreover, the ordinal categorical
outcomes are naturally in ascending or descending order. Therefore, GOR
is a preferable and superior eect measure in meta-analysis for the ordinal
categorical data.
Chapter 3
A QEBM for Heterogeneous
Ordinal Data
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3.1 Introduction
In recent years, there has been growing interest in meta-analysis in various
elds of health science, including analysis of RCTs. The method has im-
pacted signicantly on the practice of clinical trials and health care policies.
It allows to combine results of independent studies to increase statistical
power of the eect size estimate through increased sample size.
The development of the meta-analysis for the binary outcomes is primarily
based on the relative risk (RR) and odds ratio (OR). However, in many
clinical and epidemiological studies the outcome variables are ordinal and
have more than two categories. For example, outcomes of the study on pain
relief, dementia, head injury, tonsil size etc are measured on ordinal scales.
The commonly used eect size measures for binary outcomes can not be
directly used if the data is ordinal with more than two categories. The idea
of collapsing the 2  L; (L > 2) tables into 2  2 tables are often arbitrary
and leads to loss of valuable information. The generalised odds ratio (GOR)
(Agresti, 1980) is an appropriate measure to estimate the eect size of ordinal
categorical outcomes in meta-analysis.
There are some advantages of the GOR over its competitors. Using the
GOR in meta-analysis one can overcome the assumption needed in propor-
tional odds model (Whitehead et al., 2001). The GOR can also be used in
multi-arm trials. For binary outcomes with two comparison groups the GOR
reduces to the ordinary OR. So the GOR can be a universal eect measure
in meta-analysis with ordinal data as we can use it for binary, ordinal and
continuous outcomes.
One of the main issues in meta-analysis is the heterogeneity of the eect
size. The use of random eects model is not always a cure (Shuster, 2010;
Doi SA et al., 2011) for the problem. Thompson and Pocock (1987) ar-
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gued that meta-analysis provides simple solution of combining several studies
with respect to qualitative conclusions but fails to provide conclusive quan-
titative results for broad treatment policies when there exists heterogeneity
among the studies. \Doing meta-analysis is easy", says Ingram Olkin but
\Doing one well is hard" as heterogeneity among studies may lead to incor-
rect meta-analysis (Mann, 1990). In this chapter, a quasi-empirical Bayes
method (QEBM) (Saleh, 2006, p.157) is developed using the predicted GOR
to handle the heterogeneity issue in the light of Stein's shrinkage estima-
tor (Stein, 1956). This QEBM involves a heterogeneity test based on the
chi-square statistic (Cochran, 1954) and shrink the estimator towards the
common pooled value. This process identies the extreme studies and nds
a statistical agreement to improve the quality of the estimator and trustwor-
thiness of meta-analysis.
This chapter also implements the above method in two real life and one
simulated ordinal data sets. The main reason to consider three examples
is to illustrate the eectiveness of the method for data sets with varying
degree of heterogeneity. If the eect sizes of individual studies are not sig-
nicantly heterogeneous the meta-analysis produces acceptable results but
studies with high degree of heterogeneity require special attention and the
method proposed adequately deals with the issue.
3.2 Quasi-Empirical Bayes Method for GOR
The use of the empirical Bayes (EB) approaches has received enormous at-
tention in the literature (Van Houwelingen and Stijnen, 1993; Efron, 1996;
Raudenbush, 1985; Zhou, 1996; Morris, 1992; Stijnen and Van Houwelingen,
1990 and Saleh, 2006). But EB is rather dicult to dene precisely. Some
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statisticians refer it to a class of models; others, a style of analysis; still oth-
ers, a philosophy for screening statistical procedures. However, all the EB
methods almost exclusively assumed that the `prior distribution' has been at
the second level of the Bayesian analysis and that the hyper-parameters have
then been estimated from data. The quasi-empirical Bayes approach results
in a similar or an approximation of the EB estimation approach, hence, the
name \quasi-empirical Bayes estimation (QEBE)". Following Saleh et al.
(2006) a QEBM has been developed using GOR for heterogeneous ordinal
categorical data.
Here the initial objective is to assess the exposure disease association
by the common pooled GOR, say  0. However, it is uncertain whether the
GORs,  i's of the k independent studies are homogeneous or not. That is,
rst we estimate the vector  = ( 1; 2; : : : ; k)
0 when the hypothesis,
H0 :  1 =  2 =    k =  0 (3.1)
is unknown. For J = 2, the ith study is modeled as two multinomial distri-
butions with parameters (ni1:, i1:) and (ni2:, i2:) for a 2  L contingency
table in RCTs. Then the GOR of the ith study is dened as
 i = (di)
 1ci (3.2)
and estimated as   = ( 1;    ; k)0 by the vector ~ n = (~ 1;    ; ~ k)0, where
 ^i = (^di)
 1^ci; (3.3)
in which ^ci =
PL 1
r=1
PL
s=r+1 ^irj1^isj2 and ^di =
PL
r=2
Pr 1
s=1 ^irj1^isj2.
If the null hypothesis is true, there are three choices of ecient estimators
of the pooled GOR,  0. These are
(i) weighted arithmetic mean,
 ^
(a)
0n = !^
 1
 
kX
i=1
!^i~ i
!
; with !^ =
kX
i=1
!^i; (3.4)
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(ii) weighted geometric mean,
 ^
(g)
0n = exp
"
!^ 1
 
kX
i=1
!^i ln ~ i
!#
; (3.5)
(iii) weighted harmonic mean,
 ^
(h)
0n = !^
 
kX
i=1
!^i~ 
 1
i
! 1
; (3.6)
where
!^ 1i =
L 1X
l=1
2X
j=1
1
nij:^ijl(1  ^ijl) : (3.7)
We employ the weighted geometric mean, formula (3.5) to obtain  ^0n. For
large samples the distributions of ln ^i and ln ^0n are approximately normal,
so the formula exp[ln ^i  z=2! 1=2i ] is appropriate to obtain a 100(1  )%
CI for the GOR of the ith study and exp[ln ^0n  z=2! 1=2] for the meta-
analysis, where z=2 is the (1 =2) level critical value of the standard normal
distribution, N(0; 1).
When the k study eects are homogeneous, i.e.,  1 =  2 =    =  k =  0,
a vertical line representing the pooled GOR ( ^0n) crosses through the CI
for every trial demonstrating the power of meta-analysis to nd statistical
agreement. When there is suspicion about heterogeneity, then whether meta-
analysis is trusted or not depends on the outcome of the test of homogeneity
of the GORs, H0 :  1 =  2 =    =  k =  0 against the alternative, HA:
at least one of the pairs ( i; i0) dier (i; i
0 = 1; : : : ; k). We can test this
hypothesis using the test statistic, Ln, dened by
Ln = ( ~ n    ^0n1k)0dW n( ~ n    ^0n1k); (3.8)
where  ^0n = ln( ^0n), ~ i = ln( ^i), ~ n = ( ~ 1; : : : ; ~ k)
0, 1k = (1; : : : ; 1)0-
a k-tuple of 1's and dW n = diag(!^1; : : : ; !^k) is a consistent estimator of
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W = diag(!1; : : : ; !k). Note that n =
Pk
i=1(ni1: + ni2:). As n ! 1, Ln
follows approximately a central chi-squared distribution underH0 with (k 1)
degrees of freedom (df). This test statistic measures the departure of the
k GORs from their common GOR. Thus, for the test decision at the -
level, compare the observed value of Ln to the critical value of the chi-square
distribution with (k 1) df. Then H0 is rejected at the -level if the observed
Ln > 2k 1(). Now an estimator of   = ( 1; : : : ; k)0 say
 ^PTn = exp( ^
PT
n ) is dened as
 ^
PT
n =
8><>:  ^0n1k ifLn < 
2
k 1()
~ n ifLn  2k 1();
(3.9)
which is a choice between the two estimators based on the test outcome. This
estimator is known as the preliminary test estimator (PTE) of   (cf. Saleh,
2006, p.55). The PTE is a precursor to the Stein's shrinkage estimator and
was proposed and investigated by many authors (Bancroft, 1944; Han and
Bancroft, 1968; Khan and Saleh, 1997; Khan and Hoque, 2002; Khan, 2003;
and Khan, 2008).
The PTE depends on the choice of . For a better estimator of  , the
estimator is made dependent on the test statistic, Ln instead of the level
of signicance to produce a Stein-type shrinkage estimator (SE) dened as
 ^Sn = exp( ^
S
n), where
 ^
S
n =  ^0n1k + (1  (k   3)L 1n )( ~ n    ^0n1k); (k  4) : (3.10)
Details on the derivation of the SE can be found in Stein (1956). If Ln !1,
then  ^
S
n ! ~ n and if (k   3)L 1n is near 1, then we choose  ^0n1k, which is
similar to PTE of  . The estimator  ^
S
n is similar to the empirical Bayes type
estimator (Saleh, 2006, p.154) and known as quasi-empirical Bayes estimator
of  . Another modication to  ^
S
n is given by  ^
S+
n = exp( ^
S+
n )
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 ^
S+
n =  ^0n1k +

1  (k   3)L 1n

I()(Ln > k   3)( ~ n    ^01k); (k  4)
(3.11)
where I() is an indicator function. This estimator is similar to the positive-
rule Stein-type estimator (PRSE). Here  ^
S+
n is obtained by adjusting the
common estimate  ^0n to an amount (1 (k 3)L 1n )I(Ln > k 3)( ~ n  ^01k).
Then, we obtain k predicted values of the GORs which clusters  0n more
closely than the original GORs. Moreover, the 100(1   )% CI set has at
least 100(1   )% as the coverage probability, which may reach close to 1
near the null hypothesis of the equality of the eect measure (Hwang, 1982).
If the number of studies are greater than 4, one is advised to use  ^
S+
n for
statistical inference; otherwise, PTE may be used (Casella, 1985) and details
about the importance of shrinkage estimators in statistical literature can be
found in Efron (1995), Judge and Bock, 1978 and Saleh, 2006, 125  211.
3.3 Improved Meta-Analysis
Pooling the study eect for homogeneous studies in meta-analysis has an
statistical agreement of using a common study eect of the studies, while
using a common pooled study eect for the heterogeneous studies lacks such
an statistical agreement. To get rid of the problems of interpretation in the
case of single weighted averages of heterogeneous GORs, we apply the fol-
lowing improved meta-analysis methodology (Saleh et al., 2006): Firstly, a
common value of the GOR is computed as if the hypothesis of homogeneous
eect sizes was not rejected. Secondly, a test of signicance for homogene-
ity is conducted using the divergent statistic, Ln from equation (3:8) which
measures the departure of each of the log GORs from the sample pooled
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log GOR. Finally, to produce the predicted GOR (PGOR), the treatment
eect is estimated combining the test of homogeneity (heterogeneity) with
the usual estimated GORs to achieve the shrinking towards to pooled GOR.
The process subsumes the eect of heterogeneity, and is computed by the
following formula:
Ln( ^iP ) = pooled ln( ^) + c(observed ln( ^i)  pooled ln( ^)); (3.12)
where  ^iP = PGOR,  ^i = estimated GOR, c = 1   [degree of freedom] 2
2 value .
The computational formula for 100(1 )% CIs for individual eect size and
meta-analysis are given by
exp[ln( ^iP ) z=2! 
1
2
i ]; (3.13)
and
exp[ln( ^P ) z=2!  12 ]; (3.14)
where z=2 is the 100 =2 percentage point of a standard normal distribu-
tion.
3.4 Applications
In this section, three dierent meta-analyses on several studies with dierent
degree of heterogeneity are investigated. The rst example, tacrine trials of
Alzheimer's disease with insignicant heterogeneity and the second example,
misoprostol trials with moderately insignicant heterogeneity are presented
in subsections 3:4:1 and 3:4:2 respectively. The third example, simulated
trials with signicant heterogeneity is provided in subsection 3:4:3. The three
examples clearly illustrate detailed implementation process and usefulness of
the proposed method.
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3.4.1 Tacrine Trials: Insignicant Heterogeneity
The rst example uses data from Whitehead et al. (2001) consisting of 5
RCTs of the anti-cholinesterase drug tacrine in patients with Alzheimer's
disease. The categories of this trials are made by the Clinical Global Im-
pression of Change scale (CGIC). The CGIC is based on a seven point scale
where 1, 2 and 3 represent `very much improved', `much improved' and `mini-
mally improved', 4 indicates `no change', and 5, 6 and 7 represent `minimally
worse', `much worse' and `very much worse'. To make the example simple
and illustrate the computations, we combine categories 1, 2, and 3 repre-
senting `improvement' and categories 5, 6 and 7 representing `worse' to make
three ordered categories (improvement, no change and worse).
The display in Figure 3:1 for the GOR and the associated 95% CIs show
that the vertical line at the pooled GOR (1:58) goes through all the CIs of
the eects of these trials. Hence the display suggests that these studies are
homogeneous. This conclusion is also supported by the divergent statistic
in equation (3:8), which is exactly the same as the Q-statistic. For the
given data Ln = 1:83 with 4 degrees of freedom. So the null hypothesis
of equality of the GORs is not rejected at the 5% level of signicance (p-
value = 0:7667). The heterogeneity statistic (Higgins and Thompson, 2002)
I2 = 0%[0%; 98:03%] also suggests that these trials are homogeneous.
Table 3:1 shows the GORs, their 95% CIs (CI1), and the predicted GORs
(PGORs) and their 95% CIs (CI2). Meta-analysis of these trials is found to
be 1:58 indicating that there are 1:58 times as many tacrine-placebo pairs in
the sample for which tacrine has improved the alzheimer's disease as there
are pairs for which placebo has improved the alzheimer's disease. The forest
plot, divergent statistic, and I2 statistic give the same impression that the
eects of the tacrine trials to be homogeneous and the values of the predicted
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Figure 3.1: 95% CIs for GOR (solid horizontal lines) and predicted GOR
(dashed horizontal lines) for tacrine trials
GOR are still concentrating around the common weighted average. Clearly
both the GOR and PGOR based CIs are crossing the vertical line at the
pooled eect. This is expected for any meta-analysis with homogeneous
study eects. Statistical programming in R has been used for computation
and plots through out this thesis.
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Table 3.1: Five randomised trials of anti-cholinesterase drug tacrine
Study Treat. W NC I Total Weight GOR CI1 PGOR CI2
1 Tacrine 24 45 27 96 15.38 1.27 (0.56, 2.91) 1.62 ( 0.71, 3.69)
Placebo 32 54 24 110
2 Tacrine 60 180 133 373 15.64 1.18 (0.52, 2.69) 1.63 (0.72, 3.69)
Placebo 14 35 23 72
3 Tacrine 11 24 33 68 7.57 1.31 (0.40, 4.26) 1.61 (0.50, 5.23)
Placebo 13 17 23 53
4 Tacrine 79 175 127 381 36.26 2.08 (1.21, 3.56) 1.54 (0.90, 2.65)
Placebo 65 73 32 170
5 Tacrine 3 19 17 39 25.14 1.55 (0.81, 2.95) 1.59 (0.83, 3.03)
Placebo 8 18 15 41
Meta 1.58 ( 1.15, 2.19)
Here W = Worse, NC = No change and I = Improved are the three rearranged ordered categories from
the Clinical Global Impression of Change scale (CGIC), Total = W+NC+I, CI1 = condence intervals
of GORs and CI2 = condence intervals of PGORs.
3.4.2 Misoprostol Trials: Moderately Insignicant Het-
erogeneity
This subsection uses 10 randomised trials of misoprostol from Whitehead and
Jones (1994) investigating the prevention of injury to the gastric mucosa.
The subjects had no damage at the initial endoscopy. The results of the nal
endoscopy were used as the primary response variable. The extent of the
damage was recorded in the form of the ordered categorical score for these
studies. The data can be tted into a j  l contingency table, where j = 2,
represents the number of comparison groups and l = 2, 3, 4 and 5 represent
the number of outcome categories. Studies 1   6 and 12 used ve ordered
categories and studies 7  8 and 11 used 3 ordered categories. Studies 9  10
have only two categories. The second category in studies 9   10 are the
same as the 5th category of studies 1   6 and 12, third category of studies
7 8 and 11 and study 13 had no such outcome category representing `ulcer of
any size'. Pooling for meta-analysis of all these studies may be inappropriate.
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Therefore, we have rearranged these categories to three ordered categories
(1 = 1, 2 + 3 + 4 = 2 and 5 = 3 for studies 1   6 and 12) namely, `1 = no
erosions', `2 = erosions', and `3 = ulcer' so that we can nd the pooled GOR.
We exclude studies 9  10 and 13 as they do not meet the inclusion criteria.
Table 3.2: Randomised trials of misoprostol by endoscopic classication.
Study Treat. NE E U T W GOR CI1 PGOR CI2
1 Misop. 21 8 0 29 6.94 28.53 (4.35, 187.10) 8.65 (1.32, 56.70)
Placebo 2 15 13 30
2 Misop. 17 13 0 30 1.86 68.64 (1.82, 2583.20) 12.31 (0.33, 463.20)
Placebo 0 17 13 30
3 Misop. 20 10 0 30 10.96 5.45 ( 1.22, 24.30) 4.45 (1.00, 19.90)
Placebo 8 17 5 30
4 Misop. 20 8 2 30 1.84 23.12 (0.60, 894.60) 7.95 (0.21, 307.6)
Placebo 0 12 17 29
5 Misop. 1 9 0 10 1.27 15.71 (0.19, 1277.50) 6.81 (0.08, 553.60)
Placebo 0 4 6 10
6 Misop. 93 9 1 103 19.99 3.13 (0.99, 9.10) 3.49 (1.15, 10.60)
Placebo 85 24 5 114
7 Misop. 61 12 0 73 21.39 3.12 (1.07, 9.10) 3.56 (1.22, 10.40)
Placebo 49 28 3 80
8 Misop. 45 1 0 46 3.79 3.99 (0.31, 50.70) 3.92 (0.31, 49.90)
Placebo 65 6 3 74
11 Misop. 30 1 1 32 4.51 10.72 (0.81, 85.60) 5.27 (0.51, 54.30)
Placebo 20 11 7 38
12 Misop. 56 20 0 76 27.45 1.75 (0.68, 4.50) 2.82 (1.09, 7.30)
Placebo 50 32 0 83
Meta 3.88 (2.36, 6.37)
Here, NE = no erosions, E = erosions, U = ulcer, T = total, W = weight, CI1 = condence intervals of
GORs, CI2 = condence intervals of PGORs.
So the rearranged data represents a 2  3 contingency table for each of
these studies. Studies with zero cell frequencies are analysed adding 1=3 to
every cell of each of the 2 3 table.
In Table 3:2, we present the GOR and predicted GOR values of these
trials along with their CIs. The chi-square value Q = 11:71, df = 9, and p-
value = 0:2304 suggest insignicant heterogeneity. I2 = 23:12% [0%; 62:58%]
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Figure 3.2: 95% CIs for GOR (solid horizontal lines) and predicted GOR
(dashed horizontal lines) for the randomised trials of misoprostol by endo-
scopic classication
suggesting 23:12% of the variability is due to the heterogeneity. Thus, there
exists insignicant heterogeneity. Figure 3:2 depicts the CIs of the original
GORs in solid horizontal lines and predicted GORs in dashed horizontal
lines. It is observed that the vertical line at the common pooled GOR = 3:88
is passing through all the CIs of the original GORs except the rst study.
The calculated predicted GORs are more concentrated around the pooled
GOR and also the vertical line of the pooled GOR is now crossing all the CIs
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of the predicted GORs suggesting a justication of the use of PGORs. Thus,
we have shown that the use of predicted GORs are improving the estimates of
the GORs with ordinal data in meta-analysis in the presence of insignicant
heterogeneity. This is also discussed elaborately in subsection 3:4:3 in the
context of signicant heterogeneity.
3.4.3 Simulated Trials: Signicant Heterogeneity
In this section, we generate data for 10 studies using the multinomial sam-
pling procedure. For simulation the cell probabilities are selected in such a
way that the outcomes are heterogeneous in order to show the eectiveness
of the proposed procedure in heterogeneous data. The simulated data is
presented in Table 3:3 along with their weights, GORs, CIs of GORs (CI1),
PGORs, CIs of PGORs (CI2) and the common GOR. For the simulated data
the heterogeneity statistic Ln = 32:24 with p-value = 0:0001 and I2 = 72:09%
[47:06%; 85:28%]. The pooled GOR for these trials is 1:48.
In Figure 3:4 the graphical representation shows rays emitting from the
pooled GOR to the GORs and the predicted GORs on the vertical lines
labeled as the GORs and predicted GORs. The display suggests that the
predicted GORs are shrinking towards the pooled GOR. It is observed from
Figure 3:3 that the CIs of some studies, for example studies 1, 4, 5, 7, 9 and
10, have moved to the right while that for studies 2, 3, 6 and 8 have moved
to the left. The vertical line at the common GOR does not go through all
the CIs of these trials. The CI for the study 2 is away to the right while that
for the study 4 is away to the left from the common GOR at 1:48.
This indicates that study 2 with GOR = 6:28 and study 4 with GOR
= 0:22 may be with extreme eect sizes. We compute the Ln statistic by
excluding one extreme study at a time. After excluding study 2 we nd
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Table 3.3: Ten simulated heterogeneous studies.
Study Groups C1 C2 C3 T W GOR CI1 PGOR CI2
1 Treatment 2 24 3 29 3.91 1.18 (0.12, 11.24) 1.24 (0.13,11.81)
Placebo 3 22 5 30
2 Treatment 24 5 1 30 11.51 9.38 (2.52, 34.83) 6.28 (1.69,23.34)
Placebo 7 19 4 30
3 Treatment 26 1 3 30 3.02 8.62 (0.67, 111.55) 5.88 (0.45,76.12)
Placebo 4 21 5 30
4 Treatment 2 24 4 30 6.93 0.13 (0.02, 0.70) 0.22 (0.04,1.19)
Placebo 18 9 2 29
5 Treatment 1 8 1 10 1.30 0.01 (0.00, 0.60) 0.03 (0.00,1.71)
Placebo 9 1 0 10
6 Treatment 8 84 11 103 13.74 4.39 (1.32, 14.60) 3.47 (1.04,11.53)
Placebo 18 10 86 114
7 Treatment 16 50 7 73 35.95 1.46 (0.69, 3.07) 1.46 (0.70,3.08)
Placebo 14 53 13 80
8 Treatment 37 1 8 46 3.91 3.93 (0.41, 37.34) 3.18 (0.33,30.22)
Placebo 14 55 5 74
9 Treatment 7 19 6 32 8.16 0.29 (0.06, 1.37) 0.41 (0.09,1.96)
Placebo 26 6 6 38
10 Treatment 3 64 9 76 11.57 0.78 (0.21, 2.91) 0.90 (0.24,3.34)
Placebo 11 59 13 83
Meta 1.48 (0.95, 2.31)
Here C1=category 1, C2=category 2, C3=category 3, T=total, W=weight, CI1=condence intervals of
GOR, CI2=condence intervals of PGOR.
Ln = 23:67 with p-value = 0:0048 and I2 = 66:20% [31:46%; 83:33%]. This
implies rejection of the null hypothesis of the equality of the GORs with a
reduction of 8:67 from the chi-square value of original 10 studies. The pooled
GOR excluding study 2 is 1:17. Dropping study 4 yields the same values for
Ln and I2. This also suggests rejection of the null hypothesis. The pooled
GOR of the remaining 9 study eects is 1:78. This directs us to exclude
study 4 from the meta-analysis as study 2 contains more information than
study 4 in terms of relative weight. Dixon's test (Dixon, 1950) for outliers
also produces the same result. Thus, we recompute the predicted GORs
excluding study 4 and present the recalculated results in Table 3:4 along
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with the 95% CIs.
Study 1
Study 2
Study 3
Study 4
Study 5
Study 6
Study 7
Study 8
Study 9
Study 10
Pooled
1.480 1 4 6
Generalised Odds Ratio (log−scale)
Figure 3.3: The horizontal solid lines represent CIs of GOR and dashed-lines
CIs of predicted GOR
The graphical display in Figure 3:5 shows that the predicted GOR values
are now more concentrated around the pooled common GOR (= 1:78) and
the vertical line at the new common GOR at 1:78 goes through all the CIs of
the predicted GORs. This suggests a statistical agreement about the power
of the new meta-analysis which was initially rejecting the null hypothesis of
equality at the 5% level of signicance. Therefore, the common GOR value
of 1:78 implies that there are 1:78 times as many treatment-placebo pairs in
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1.48
1.18 Study 1
9.38 Study 2
8.62 Study 3
0.13 Study 40.012 Study 5
4.39 Study 6
1.46 Study 7
3.93 Study 8
0.29 Study 9
0.78 Study 10
1.24 Study 1
6.28 Study 2
5.88 Study 3
0.22 Study 40.03 Study 5
3.47 Study 6
1.46 Study 7
3.18 Study 8
0.41 Study 9
0.90 Study 10
GOR Predicted GOR
0
10
Figure 3.4: Display of original GOR and predicted GOR from ten simulated
heterogeneous trials
the sample for which the treatment improve the disease as there are pairs
for which placebo improve the disease. It is evident from this analysis that
the PGORs provides statistically valid meta-analysis for ordinal data from
heterogeneous trails. Figure 3:6 depicts the improvement in the homogeneity
of the predicted GORs after deletion of the extreme trial. In this study, we
have shown that the traditional meta-analysis has been improved using the
quasi-empirical Bayes estimation and the Dixon's test of outliers. These
improved estimates of the GORs along with their CIs make easier to redress
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1.18 Study 1
9.38 Study 2
8.62 Study 3
0.012 Study 5
4.39 Study 6
1.46 Study 7
3.93 Study 8
0.29 Study 9
0.78 Study 10
1.31 Study 1
6.15 Study 2
5.78 Study 3
0.04 Study 5
3.49 Study 6
1.53 Study 7
3.21 Study 8
0.46 Study 9
0.97 Study 10
GOR after
deleting study 4 
Predicted GOR
deleting study 4 
0
10
Figure 3.5: Display of GOR and predicted GOR values after deleting Study
4
the issue of heterogeneity among diverse studies for ordinal data in order to
ensure the validity and trustworthy meta-analysis.
3.5 Conclusion
Heterogeneity is one of the most problematic aspects in many meta-analyses.
We have demonstrated a method to remedy the problem of heterogeneity in
meta-analysis for ordinal categorical data. To improve the pooled estimator
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Study 1
Study 2
Study 3
Study 5
Study 6
Study 7
Study 8
Study 9
Study 10
Pooled
1.780 1 4 6
Generalised Odds Ratio (log−scale)
’’
Figure 3.6: 95% CIs after deleting Study 4
Table 3.4: Predicted GOR of nine trials deleting Study 4
Study Study 1 Study 2 Study 3 Study 4 Study 5
GOR 1.18 9.38 8.62 deleted 0.012
95%CI (0.12,11.25) (2.52,34.84) (0.67,111.55) deleted (0.00,0.60)
PGOR 1.31 6.15 5.78 deleted 0.043
95%CI (0.14,12.47) (0.48,79.61) (1.06,31.33) deleted (0.00,2.13)
Study Study 6 Study 7 Study 8 Study 9 Study 10
GOR 4.39 1.46 3.93 0.29 0.78
95%CI (1.32,14.60) (0.69,3.07) (0.41,37.34) (0.06,1.37) (0.212,2.91)
PGOR 3.49 1.53 3.21 0.46 0.97
95%CI (1.05,11.61) (0.73,3.22) ( 0.34,30.54) (0.10,2.17) (0.26,3.58)
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a quasi-empirical Bayes method based on the preliminary test approach is
presented. The use of the predicted GOR improves the meta-analysis signif-
icantly in terms of shrinking the CIs of the study eects towards the pooled
eect. Three examples are discussed with dierent degree of heterogeneity.
The standard meta-analysis for homogeneous studies are simple and straight-
forward. We have shown that our method improves the meta-analysis in the
presence of insignicant and signicant heterogeneity. With the use of the
predicted GOR the vertical line at the pooled GOR is passing through all
the CIs of the eect measures suggesting an statistical agreement of using
the new pooled eect measure. For insignicant heterogeneity we do not
need to exclude any study whereas for signicant heterogeneity the method
suggests to exclude the extreme study. After excluding the extreme study,
the statistical agreement in terms of shrinking the CIs of the study eects
towards the pooled eect is achieved.
Dropping extreme studies without further investigation of the clinical
reasons is unwise and unwarranted. Normally clinicians would search for
any reasonable factors that may have caused it, and explain its reasons and
impact. However, standard meta-analysis leads to invalid and misleading
interpretation and conclusion when the studies are heterogeneous (Saleh et
al., 2006). The proposed method provides a procedure to conduct valid
meta-analysis of ordinal data in the presence of heterogeneity. The graphical
analysis (ray plot) is an integral part of the method that is very useful in un-
derstanding the mechanism that improves the meta-analysis by implementing
the idea of shrinking and using the test of homogeneity.
Chapter 4
GOR for Binary Outcomes: A
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4.1 Introduction
For binary outcomes relative risk (RR) and odds ratio (OR) are widely used
as eect measures to analyse data produced by RCTs. In this chapter, we
employ GOR to measure eect size of binary outcomes in meta-analysis of
RCTs. The GOR can be a very useful eect measure in meta-analysis not
only for binary outcomes but also for more than two outcome categories in
RCTs (Hossain and Khan, 2011). It is simple to compute and its interpre-
tation is very straightforward. It can be used for the continuous ordinal
outcomes in RCTs. It can also be used with multi arm trials (more than two
comparison groups).
In this chapter, we cover the xed eects model (FEM) (Birge, 1932;
Cochran, 1937) and random eects model (REM) (DerSimonian and Laird,
1986) using ordinary OR. Three alternative methods for combining results
from binary outcomes are also presented for meta-analysis. The rst alterna-
tive method is based on the sample size weight using ORG. This is a FEM
devised from Edwardes and Baltzan (2000). The other alternative methods
use weights from the estimated variance under independent binomial dis-
tribution using GOR as the eect measure. Of these, the rst method is
a FEM approach using GOR and the second method is a REM approach
using GOR. The results from a meta-analysis of six RCTs (Memon et al.,
2011) evaluating the ecacy and drawbacks of limited (D1) versus extended
lymphadenectomy (D2) for proven gastric adenocarcinoma are compared.
4.2 GOR: As Binary Eect Measure
Consider a RCT setting for binary outcomes as in Table 4:1.
The generalised odds ratio (GOR) can be used for such binary outcomes.
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Table 4.1: Data of a single RCT
Groups Failure/Dead Success/Alive Size
Treatment a = X11 b = X12 n1: = a+b
Placebo c = X21 d = X22 n2: = c+d
In fact, GOR can be used as an eect measure for a number of situations
in meta-analysis, such as for binary outcomes, more than two ordinal cate-
gory outcomes and latent continuous outcomes. It has been widely used in
psychology and education disciplines for over 30 years. The GOR for the ith
study is dened as
 i = (d)
 1c; (4.1)
where c =
PL 1
r=1
PL
s=r+1rj1sj2 and d =
PL
r=2
Pr 1
s=1rj1sj2. For binary
outcomes L = 2, so  i is estimated by its maximum likelihood estimator, say
 ^i, as
 ^i = (^d)
 1^c = (^2j1^1j2) 1^1j1^2j2 =
ad
bc
; (4.2)
where c denotes the probability that the response of a randomly selected
subject from group 2 is severer than the response of a randomly selected
subject from group 1, and d denotes the probability that the response of
a randomly selected subject from group 1 is severer than the response of a
randomly selected subject from group 2.
4.3 Review of Methods using OR and ORG
In this section we discuss the widely used general FEM (Birge, 1932), (Cochran,
1937) and standard REM (DerSimonian and Laird, 1937) for binary outcomes
using OR in meta-analysis. A great debate is going on over which model is
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theoretically and/or practically superior. Although REMs have been crit-
icised for its unrealistic distribution assumptions (Peto, 1987), it has been
argued that they are consistent with the standard specic aims of generali-
sation (Raudenbush, 1994). Greenland (1994) showed that REMs are more
sensitive to publication bias, as those oer greater relative weight to smaller
studies. Now-a-days, many meta-analyses employ both FEM and REM for
the same set of studies as neither FEM nor REM can be considered as ideal
(Thompson, 1993). Although when there is no evidence of heterogeneity, the
REM produces the same pooled estimate as of FEM. However, when there
is evidence of heterogeneity, FEMs can not take into account this extra vari-
ation, whereas REMs do. That indicates a REM may still be worth using as
it can not be assumed that true homogeneity exists (Thompson and Pocock,
1991).
However, Shuster (2010) put into serious question the validity of em-
pirically based weighting in random eects meta-analysis and proposed two
alternative methods. The rst method estimates the arithmetic mean of the
population of study eect sizes according to the classical model for random
eects meta-analysis and the second method estimates a patient level ef-
fect size. In response to the criticism of Waksman, (2010), Thompson and
Higgins, (2010), Laird et al, (2010), and Rucker et al (2010), Shuster et al
(2010) wrote \we continue to recommend that past meta-analyses which have
inuenced public policy or clinical paradigms be reanalyzed by unweighted
methods".
Now to discuss the FEM and REM for OR let us consider  ^i is an estimate
of the true eect size i in the ith study as  ^i = i + ei, where ei is the
error with which  ^i estimates i. For the FEM, var( ^i) = vi and for REM
var( ^i) = 
2
 + vi, where 
2
 is the between study variance and vi is the
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variance due to sampling error for the ith study. If  2 = 0, the above REM
would reduce to the FEM.
4.3.1 Fixed Eects Model
The inverse variance-weighted method is one of the most widely used method
among the FEMs in meta-analysis. To illustrate this, consider Ti is the
observed estimate for ith study eect with variance vi and i is the underlying
population eect size, where i = 1;    ; k.
Assuming Ti to be normally distributed, an approximate 100(1   )%
condence interval (CI) for the ith study eect, i, is given by
Ti   z=2
q
1=!i  i  Ti + z=2
q
1=!i; (4.3)
where z=2 is the =2 percentage point of a standard normal distribution and
!i =
1
vi
: (4.4)
Then assuming 1 = 2 =;    ; k = , a pooled estimate of the treatment
eect is given by
T : =
P
i !i iP
i !i
: (4.5)
An estimator of the variance of the pooled estimate T : is given by
var( T :) = 1=
kX
i=1
!i: (4.6)
If T : is assumed to be normally distributed, an approximate 100(1 )% CI
for the population eect, , is given by:
T :  z=2
vuut1= kX
i=1
!i    T :+ z=2
vuut1= kX
i=1
!i; (4.7)
where z=2 is the =2 percentage point of a standard normal distribution.
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4.3.2 Random Eects Model
Consider ^ 2 denote the estimate of the between study variance of the study
eect sizes  2 . Dene ! and s
2
W to be the mean and variance of the weights
from the k studies:
! =
kX
i=1
!i=k (4.8)
and
s2W =
1
k   1
 
kX
i
!2i   k!2
!
: (4.9)
Further, dene
U = (k   1)
 
!   s
2
W
k!
!
(4.10)
and
Q =
kX
i=1
!i(Ti   T :)2; (4.11)
whereQ is the heterogeneity test statistic, (also known as Cochran's 2 statis-
tic) for testing the H0 = 1 = 2 =;    ; k = . The estimated component of
variance due to inter-study variation in eect size ^ 2 , is calculated as
^ 2 =
8><>: 0 if Q  k   1(Q  (k   1))=U if Q > k   1: (4.12)
Then adjusted weights !i for each of the studies can be calculated as
!i =
1
[1=!i] + ^ 2
: (4.13)
A 100(1  )% CI for i is given by
TiR   z=2=
q
!i  i  TiR + z=2=
q
!i (4.14)
under the assumption of normality of TiR, where TiR represents the observed
estimate of the ith study eect size under REM. The point estimate for the
mean treatment of all studies, , can be computed by
T :R =
kX
i=1
!i Ti=
kX
i=1
!i : (4.15)
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The variance of this estimate is
var( T :R) = 1=
kX
i=1
!i ; (4.16)
and if normality of T :R is assumed, a 100(1  )% CI for  is given by
T :R   z=2=
vuut kX
i=1
!i    T :R + z=2=
vuut kX
i=1
!i : (4.17)
4.3.3 Sample Size Weight Method
Here we adopt the sample size weight method (Edwardes and Baltzan, 2000)
for binary data pooling in meta-analysis. This method does pooling Good-
man and Kruskal's  = (ad   bc)=(ad + bc) instead of pooling ORG =
(1 + )=(1  ) using the sample size weights TN =n1n2=(n1 + n2) as
 =
X
i
TNii=
X
i
TNi (4.18)
taking i, TNi as , TN for the ith study. Data can be combined for meta-
analysis with ORG=(1 + )=(1  ).
An asymptotic standard error of log(ORG) is estimated by
SE(logORG) = 2 SE()=(1  )2 (4.19)
and a 95% CI for ORG is
fORG exp[ 3:92SE()=(1 2)];ORG exp[3:92SE()=(1 2)]g; (4.20)
where exp() is the exponential function. This model is a FEM approach.
Although the formula for the variance estimate of  is available, there is no
well dened variance estimate for the pooled ORG, and hence the CI for
pooled ORG is unavailable under this method.
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4.4 Proposed Method
The proposed method is to use GOR as an eect measure for binary out-
comes under both FEM and REM. For illustration consider  ^i representing
logarithm of GOR, the observed eect size with variance vi, and i is the
underlying population eect size. Then assuming 1 = 2 =    = k = , a
pooled estimate of the treatment eect can be obtained by
 ^0 =
P
i !i ^iP
i !i
: (4.21)
For an arbitrary number of ordered outcome categories (L) in RCTs in which
each row is modeled as an independent multinomial distribution, the esti-
mated variance, vi = !^
 1
i of the ith study eect is given by
!^ 1i =
L 1X
l=1
2X
j=1
1
nij:^ijl(1  ^ijl) ; (4.22)
where nij: is the total count of jth group for the ith study, ^ijl = Xijl=nij:
is the maximum likelihood estimator (MLE) of ijl, Xijl is the count of the
lth category in the jth group for the ith study. For binary outcomes the
estimated variance expression reduces to
!^ 1i =
2X
j=1
1
nij:^ij1(1  ^ij1) : (4.23)
Assuming  ^i's are normally distributed, an approximate 100(1  )% CI for
the GORs is given by the formula
exp[ ^i  z=2! 1=2i ]: (4.24)
An estimator of the variance of the pooled estimate  ^0 is given by
var( ^0) = 1=
kX
i=1
!i: (4.25)
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If  ^0 is assumed to be normally distributed, an approximate 100(1 )% CI
for the population eect, , is given by
exp[ ^0  z=2! 1=2]; (4.26)
where z=2 is the =2 percentage point of a standard normal distribution.
Furthermore, an asymptotic variance of  ^i (Agresti, 1980; Lui, 2004) for
binary outcomes can also be found as
var( ^i) =
2i22i11 + ( ii21)
212
ni1:2
d
+
2i11i22 + ( ii12)
221
ni2:2
d
: (4.27)
Then using the logarithmic transformation a 100(1 )% percent asymptotic
condence interval for  i can be obtained as
 ^i exp( z=2
q
var( ^i)= ^i);  ^i exp(z=2
q
var( ^i)= ^i)

: (4.28)
The above procedure is a FEM approach. For REM approach, consider ^ 2
to be the estimate of the between study variance. Dene ! and s2W to be the
mean and variance of the weights from the k studies as
! =
kX
i=1
!i=k and s
2
W =
1
k   1
 
kX
i
!2i   k!2
!
: (4.29)
Further dene
U = (k   1)
 
!   s
2
W
k!
!
and Q =
kX
i=1
!i( ^i    :)2; (4.30)
where Q is the heterogeneity statistic. The estimated component of variance
due to inter-study variation in eect size, ^ 2 , is calculated as
^ 2 =
8><>: 0 if Q  k   1(Q  (k   1))=U if Q > k   1: (4.31)
Then adjusted weights !i for each of the studies can be calculated as
!i =
1
[1=!i] + ^ 2
: (4.32)
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A 100(1  )% CI for i is given by
exp[ ^iR  z=2=
q
!i ] (4.33)
under the assumption of normality of  ^iR.
The point estimate for the mean treatment eect of all studies, , can be
computed by
 ^0R =
kX
i=1
!i  ^i=
kX
i=1
!i with var( ^0R) = 1=
kX
i=1
!i : (4.34)
If normality of  ^0R is assumed, a 100(1  )% CI for  is given by
exp[ ^0R  z=2=
vuut kX
i=1
!i ]: (4.35)
4.5 Results
This example uses data from meta-analysis of RCTs evaluating the ecacy
and drawbacks of limited (D1) versus extended lymphadenectomy (D2) for
proven gastric adenocarcinoma (Memon et al, 2011). Six trials totaling 1876
patients (D1 = 946, D2 = 930) were analyzed. The meta-analysis was pre-
pared in accordance with the Preferred Reporting Items for Systematic re-
views and Meta-analyses statement. The six outcome variables analysed
included length of hospital stay; overall complication rate; anastomotic leak
rate; re-operation rate; 30-day mortality rate and 5-year survival rate. The
outcome postoperative complication rate is chosen out of the six outcomes
studied because of its signicant heterogeneity.
We apply the above ve models for estimation and illustrate using these
six studies. The rst two models are a FEM and a REM using OR, the third
model is a FEM using ORG, the proposed last two models are a FEM and
a REM using GOR.
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Table 4.2: OR for total postoperative complications
Study Name e.t n.t e.c n.c OR CI W(f) W(r)
1 Dent 3 22 8 21 0.26 0.06, 1.15 1.98 7.23
2 Robert. 0 25 24 29 0.004 0.00, 0.08 0.52 2.20
3 Bonenk. 128 513 183 483 0.54 0.41, 0.71 60.67 32.62
4 Cusch. 55 200 92 200 0.44 0.29, 0.67 25.78 28.10
5 Degiuli 8 76 14 86 0.60 0.24, 1.53 5.18 14.36
6 Wu 8 110 19 111 0.38 0.16, 0.91 5.88 15.49
Here, e.t = events in the treatment group, n.t = total number of patients
in the treatment group, e.c = events in the control group, and n.c = total
number of patients in the control group. W(f) = weights from FEM and
W(r) = weights from REM
FEM: OR = 0:4894, 95% CI = (0:396; 0:60), z =  6:62, p-value <0.0001.
REM: OR = 0:4210, CI = (0:2683; 0:6606), z =  3:76, p-value = 0:0002.
The homogeneity statistic, Q (Cochran, 1954) using OR for these data
is Q = 11:85 with 5 df, giving p-value = 0:0369. This indicates there exists
signicant heterogeneity in the data set. Using REM of DerSimonian and
Laird (1986), we obtain ^ 2 = 0:1428. Heterogeneity statistic I2 = 57:8%
[0%; 82:9%] indicates about 58% variation is due to the between study vari-
ation.
Table 4:2 shows the data for the six studies, estimated study specic OR,
95% CI, weights for xed and random eects models. Using xed eects
model, there are 51% reduction of relative odds of developing postopera-
tive complications (OR = 0:49, CI = (0:40; 0:60), p-value < 0:0001). Under
random eects model, there are 58% reduction in relative odds of devel-
oping postoperative complications (OR = 0:42, CI = (0:27; 0:66), p-value
= 0:0002).
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Table 4.3: ORG for total postoperative complication
Study Name ORG Wf(S) CI Q/I
2
1 Dent 0.256 2.21 0.06 1.15 Q = 302:08, df = 5;
2 Robertson 0.004 3.59 0.00 22.91 p < 0.0001
3 Bonenkamp 0.545 57.64 0.415 0.715
4 Cuschieri 0.445 25.05 0.293 0.675 I2= 98.34%
5 Degiuli 0.605 5.12 0.238 1.533 [97:60%; 98:86%]
6 Wu 0.379 6.39 0.158 0.909
Meta-analysis 0.475 -
Table 4:3 contains study names, estimated ORG, sample size weight, CI
of individual ORG and values of heterogeneity statistics Q and I
2. The het-
erogeneity statistic, Q = 302:08, df = 5, p-value < 0:0001 using sample size
weights. The I2 statistic = 98:34% [97:60%; 98:86%] (Higgins and Thomp-
son, 2002). Both the values of the heterogeneity statistics for sample size
weight method are signicantly higher than other methods. Under sample
size weight method the pooled estimate ORG = 0:475. As there is no well
dened variance estimate for the pooled ORG (Edwardes and Baltzan, 2000),
we can not nd the CI for the pooled ORG.
The proposed method conducts meta-analysis both under FEM and REM
using GOR. The heterogeneity statistic Q = 11:85, df = 5, p-value = 0:0369.
This suggests presence of signicant heterogeneity among these studies. The
statistic I2 = 57:80% [0%; 82:93%]. This indicates about 58% of the total
variation is accounted for heterogeneity. Meta-analysis under FEM using
GOR = 0:49, CI = (0:40; 0:60), which means 51% reduction in relative odds
of developing postoperative complications. Under REM the meta-analysis
estimate is GOR = 0:42, CI = (0:27; 0:66). This implies there are 58%
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Table 4.4: GOR for total postoperative complications
Study Name GOR Wf(M) Wr(M) CI
1 Dent et al 0.256 1.98 7.23 (0.06, 1.15)
2 Robertson et al 0.004 0.51 2.18 (0.00, 0.08)
3 Bonenkamp et al 0.545 60.67 32.62 (0.415, 0.715)
4 Cuschieri et al 0.445 25.78 28.10 (0.293, 0.675)
5 Degiuli et al 0.605 5.18 14.36 (0.238, 1.533)
6 Chew-Wun et al 0.379 5.87 15.49 (0.158, 0.909)
Meta-analysis 0.49 0.42
95% CI (0.40, 0.60) (0.27, 0.66)
Heterogeneity test: Q = 11:85, df = 5, p-value = 0:0369,
I2 = 57:80% [0%; 82:93%]
reduction of relative odds of developing postoperative complications.
It is interesting that the meta-analysis estimates under both FEM and
REM using GOR are exactly the same using ordinary OR for both FEM and
REMs. This tells us that use of GOR for binary outcomes in meta-analysis
is as ecient as OR. The sample size weight method produces a lower pooled
estimate than the rests under FEM. This method produces extraordinarily
higher Q value and too sensitive to zero cell counts (Edwardes and Baltzan,
2000).
Standard meta-analysis works ne with homogeneous studies but how
trustworthy is meta-analysis that use a single common eect measure for
all the studies when there exists signicant heterogeneity? Because of the
issues (Shuster, 2010; Doi SA et al., 2011) of the REM, when used in a
poorly designed studies, it still results in biased estimates even though there
is statistical adjustment for eect size heterogeneity (Senn, 2007). Now how
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representative is the common meta-analysis value 0:49 under FEM or 0:42
under REM for study Robertson et al?
4.6 Improved Meta-Analysis
To overcome the problem we can apply the improved methodology for meta-
analysis. The rst step in the traditional meta-analysis produce the com-
mon eect size = 0:49. In the second step we nd the divergent statistic
Ln = 11:85, df = 5, p-value = 0:0369. It shows signicant evidence that the
treatment eects are dierent in the six trials. Thus, the interpretation of
the common weighted average of these trials raise question; to which popu-
lation of patients does the overall GOR apply? Even in meta-analysis with
evidence of homogeneity, the same diculty arises because of the existence
of buried heterogeneity in clinical trials.
Finally, we estimate the predicted GORs (PGORs), the treatment eects
combining the test of heterogeneity with the usual estimated GORs. This
process subsumes the eect of heterogeneity using the following formula.
Ln( ^iP ) = pooled ln( ) + c(observed ln( ^i)  pooled ln( )); (4.36)
where  ^iP = PGORs,  ^i = estimated GORs, c = 1  [degree of freedom] 2
2 value .
The computational formula for the 100(1  )% CIs is given by
 L = exp(ln( ^iP )  z=2! 
1
2
i )    exp(ln( ^iP ) + z=2! 
1
2
i ) =  U : (4.37)
For these six studies c = 0:7468. The six PGOR values and their 95% CI
are presented in Table 4.5. The rst two rows of the table show the original
GOR and their 95% CIs. The graphical display in Figure 4:1 shows the rays
emitting from the estimated common GOR toward the sample GORs and
the PGORs on the vertical line labeled as the predicted GOR. It is evident
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0.30 Dent
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0.53 Bonenkamp
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0
0.65
Figure 4.1: Ray plot for GOR of the six studies of gastric carcinoma
Table 4.5: Predicted GOR of six studies of gastric carcinoma
Study Dent Robert. Bonenk. Cusch. Degiuli Wu
GOR 0.26 0.00 0.54 0.44 0.60 0.38
95%CI 0.06,1.15 0.00,0.08 0.41,0.71 0.29,0.67 0.24,1.53 0.16,0.91
PGOR 0.30 0.01 0.53 0.46 0.57 0.40
95%CI 0.07, 1.36 0.00,0.28 0.40,0.69 0.30,0.69 0.23,1.45 0.17,0.97
from the display that the PGORs are more concentrated around the common
GOR at 0:49. Figure 4:2 shows the CIs for GOR (solid horizontal lines) and
CIs for PGOR (dashed horizontal lines) of the six studies. The vertical line
at common pooled value (GOR = 0:49) is passing through the CIs of all
the studies except the Robertson et al. The estimated PGOR values are
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more concentrated around the common GOR = 0:49 which corresponds to
an estimated 51% reduction of the odds of overall complications attributed
to D1. From Figure 4:2 we see that the study Robertson is away from
Dent
Robertson
Bonenkamp
Cuschieri
Degiuili
Chew−Wun
MA
0.490 1
GOR(log−scale)
Figure 4.2: 95% CI for GOR of the six studies of gastric carcinoma
the common GOR, therefore may be considered as an outlier although it
is dicult to identify the clinical reason initially. Now we compute the Ln
with the ve studies excluding Robertson. In this case Ln = 1:98, df = 4 with
p-value = 0:7389. When we apply the Dixon's test (Dixon, 1950) for outlier,
we also obtain the same result. So the null hypothesis of equality of the GORs
is accepted. The recomputed weighted average becomes 0:50. Thus using the
formula lnPGOR=ln(0:50)+c(lnGOR-ln(0:50)), where c =  0:0088, we nd
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the PGOR values. Figure 4:3 shows the ray plot and Figure 4:4 shows the
0.49
0.26 Dent
0.004 Robertson
0.54 Bonenkamp
0.44 Cuschieri
0.60 Degiuli
0.38 Chew− Wun
0.50.
GOR PGOR
0
0.65
All 5 studies
converge
to 0.50
Figure 4.3: Display of GOR and PGOR values of ve studies for gastric
carcinoma
CI plot of the ve studies excluding Robertson. The display of the PGORs
shows that these predicted values are more concentrated toward estimated
common value 0:50. The vertical dashed line at the common value 0:50 goes
through the CIs of every study, demonstrating the power of the new meta-
analysis. It is therefore statistically valid and trustworthy to combine the
GORs for a common value 0:50 for these ve studies. Figures 4.3 and Figure
4.4 show sharp improvement in the homogeneity of the PGORs after deleting
the outlier study.
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Figure 4.4: 95% CIs for GORs and PGORs of the ve studies of gastric
carcinoma
4.7 Summary
In this chapter we have compared results from ve meta-analysis methods
for binary outcomes. Meta-analyses using GOR for binary outcomes are as
ecient as OR for both FEM and REMs. This study suggests that GOR can
be used as an eect measure for binary outcomes in meta-analysis.
The sample size weighted method for binary outcomes entails lower meta-
analysis estimate as compared with the other FEMs using OR and GOR.
However, unavailability of a well dened variance estimate for the pooled
estimate, inated Q-value, sensitivity to the zero cell frequency are important
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issues of concern for this method.
Use of GOR in meta-analysis for binary outcomes along with the im-
proved methodology can facilitate achieving more valid and trustworthy
meta-analysis.
Chapter 5
GOR for Continuous Outcomes
72
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5.1 Introduction
In Chapter 4, we showed GOR as an eective binary outcome measure in
meta-analysis. In this chapter, we discuss methods in meta-analysis for con-
tinuous outcomes as well as mixture of one continuous and one categorical
outcomes.
The weighted mean dierence (WMD) is used as an eect measure for con-
tinuous outcomes for a long time. Sometimes standardised weighted mean
dierence (SWMD) is also used to pool continuous outcomes in a meta-
analysis combining parallel and cross-over trial designs (Curtin et al, 2002).
In this chapter, three methods for multilevel continuous outcomes are
considered for meta-analysis. The rst method is applicable when both the
variables are continuous in multilevel outcomes and comparison groups. The
second method is useful only when the multilevel continuous outcomes are
observed in RCTs with two comparison groups. The third method is for
multilevel continuous outcomes when those are made ordinal from two or
more comparison groups. While the second method uses mean dierence
(MD) as an eect measure, the rst and third method employ GOR (Agresti,
1980) as an eect measure. Although the rst method is moderately complex,
the other two methods are simple and straightforward.
Due to the unavailability of any real data for the multi-level continuous
outcome we present results for the third method (Table 5.2) from simulated
data sets.
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5.2 Review
5.2.1 Method 1: Continuous vs Continuous
Consider RCTs where both the treatment and outcome variables are contin-
uous. The treatment variable is represented along the rows and the outcome
variable in the columns. Let us consider two pairs of variables (Y1, Y
0
1) and
(Y2, Y
0
2) both distributed according to a bivariate distribution. When both
the variables are continuous, c + d = 1, where c is the probability that
(Y2, Y
0
2) is concordant with (Y1, Y
0
1) and d is the probability that (Y2, Y
0
2) is
discordant with (Y1, Y
0
1). Then the GOR (Agresti, 1980) can be written as
  =
(1 + )
(1  ) ; (5.1)
where  is Kendall's tau (Kendall and Gibbons, 1990; p.3) and ^ is asymp-
totically normally distributed. Then
( ^i    i)pnq
flim var( ^ipn)g
 N(0; 1); where 0 <  i <1; (5.2)
where  ^i represents the estimated GOR for the ith study. The variance
expression from Noether (1967, p.74) gives
var fn(n  1)^ =2g = 2N(N   1) c(1  c)
+ 4N(N   1)(N   2)(cc   2c ); (5.3)
where cc is the probability that the rst and the second member are both
concordant with the third for a random sample of three members.
Using the above expression, we get
lim
n!1 var( ^
p
n) = lim
n!1
var(^
p
n)
4(1  c)4
= 4
(cc   2c )
(1  c)4 : (5.4)
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For bivariate normal distribution
 i =
( + 2sin 1)
(   2sin 1) (5.5)
and it follows from Esscher (1924) that
var() =
2
n(n  1)
(
1 

2

sin 1
2
+ 2(n  2)
"
1
9
 

2

sin 1
1
2

2#)
:
(5.6)
Then,
lim
n!1 var( ^i
p
n) =
"
1
9
 

2

sin 1
1
2

2#
=
 
 + 2sin 1
2
!4
: (5.7)
Suppose Y1 and Y2 are two independent continuous random variables, then
the GOR,
 i =
P (Y2 > Y1)
f1  P (Y2 > Y1)g (5.8)
is used to compare the two distributions. Let us consider Y1 and Y
0
1 are
independent random variables from the treatment distribution and further
Y2 and Y
0
2 from the outcome distribution. Again, let P21 = P (Y2 > Y1),
P221 = P (Y1 < Y2; Y1 < Y
0
2), P211 = P (Y1 < Y2; Y
0
1 < Y2), and suppose that
random samples of sizes n1 = w1n and n2 = w2n are selected from the two
distribution so that w1 + w2 = 1. Then using the asymptotic normality of
the Mann-Whitney statistic U = number of pairs for which Y2 > Y1,  ^i is
asymptotically normally distributed with
lim
n!1 var( ^i
p
n) = 221=(1  P21)4; (5.9)
where 221 = limn!1 var(P^21
p
n) in which P^21 = U=n1n2. From Lehmann
(1975, p. 70) we have
var(U) = n1n2P21(1 P21)+n1n2(n2 1)(P221 P 221)+n1n2(n1 1)(P211 P 221):
(5.10)
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Therefore,
221 = (P221   P 221)=w1 + (P211   P 221)=w2: (5.11)
The pooled estimate of GOR can be calculated as  ^0 =
P
i
!i ^iP
i
!i
, where !i =
1=var( ^i). The CIs for individual studies under FEM can be computed using
the estimate of var( ^i) as exp[ln ^i  z=2
q
var( ^i)] and for meta-analysis
using formula exp[ln ^0  z=2=
qPk
i=1 var( ^i)].
The pooled estimate and the CI can also be constructed under REM in a
similar fashion as in Chapter two incorporating the between study variance.
5.2.2 Method 2: Categorical vs Continuous
When data from RCTs with multiple outcome categories are continuous,
Mean dierence (MD) or standardised mean dierence (SMD) can be used
as an eect measure for multilevel continuous outcome categories for two
comparison groups. Using MD one can estimate the eect measure in the
original unit of measurement while SMD has the advantage of being a unit
free measurement. The treatment eect (Ti) for the ith study is calculated
by
Ti = Xti   Xci; (5.12)
where Xti and Xci are the sample mean responses in the treatment and con-
trol groups respectively. Now the standard error of this treatment dierence
(Ti) can be found as
se(Ti) =
q
var(Ti) =
q
s2p (1=nt + 1=nc); (5.13)
where s2p =
r
(nt 1)s2t+(nc 1)s2c
nt+nc 2 is the estimate of the assumed common variance
(Hedges and Olkin, 1985), 2t = 
2
c = 
2 for the two population variances
and nt and nc are the within study sample sizes in the treatment and con-
trol groups respectively. If the population variances are assumed dierent
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se(Ti)=
q
var(Ti) =
q
s2t=nt + s2c=nc. An appropriate 95% CI for individual
study can be calculated then by Ti  1:96  se(Ti).
The weighted mean dierence (WMD) in meta-analysis under FEM can
be found as
WMD = T =
Pk
i=1 !iTiPk
i=1 !i
; (5.14)
where !i = 1=var(Ti) is the weight and Ti is the eect size for the ith study.
A 100(1 )% CI for pooled estimate can be calculated as Tz=2=
qPk
i=1 !i.
Under REM the !i's are calculated incorporating the between study vari-
ance ^ 2 as
!i =
1
[(1=!i) + ^ 2]
; (5.15)
where ^ 2 = (Q (k 1))=U if Q > k 1, 0 otherwise, U = (k 1)

!   s2W
k!

,
s2W =
1
k 1
Pk
i !
2
i   k!2

, ! =
Pk
i=1 !i=k, Q is the heterogeneity statistic and
k is the number of studies. Under normality assumption a 100(1  )% CIs
for individual eect size estimate and pooled estimate can be calculated by
Ti  1:96  se(Ti) and T  z=2=
qPk
i=1 !

i respectively.
Standardised Mean Dierence
The standardised mean dierence (SMD) is estimated by
di =
Xti   Xci
s
; (5.16)
where Xti and Xci are the sample mean responses in the treatment and
control groups respectively, and s is the pooled estimate of the standard
deviations as before. The estimate di has small sample bias and the bias
can be removed using a simple correction (Hedges, 1981) that produce an
unbiased estimate of the population SMD. The variance of di is dicult to
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compute exactly. However, a very good approximation of the variance of di
is given by
Vdi =
nti + nci
ntinci
+
d2i
2(nti + nci)
: (5.17)
More simpler variance approximation (Fleiss, 1993) is also available if the nti
and nci are large and the population variances are equal as
Vdi =
nti + nci
ntinci
: (5.18)
The use of SMD has been criticised by saying that studies with identical
results may vaguely appear to yield dierent results. The transformation
can even make a study whose original estimate was smaller in magnitude
than another study appear greater and vise versa (Greenland, 1987). There
are other continuous outcome measures rarely used in medicine, such as
correlation coecient etc (Rosenthal, 1994).
5.3 Method 3: Categorical vs Latent Contin-
uous
When the continuous outcomes are made ordinal in RCTs or the outcomes are
available in continuous range, GOR is an eective outcome measure. These
data are in counts in multilevel categories. These categories are either in
ascending or descending order. As a result, we can set them as concordant or
discordant pairs with two or more comparison groups as needed. Even when
there are more than two treatment groups (multi-arm trials) with multilevel
outcomes, GOR is still a meaningful eect measure. The eect size can be
estimated using GOR as
 ^i = ^ci=^di; (5.19)
CHAPTER 5. GOR FOR CONTINUOUS OUTCOMES 79
where ^ci =
PL 1
r=1
PL
s=r+1 ^irj1^isj2 and ^di =
PL
r=2
Pr 1
s=1 ^irj1^isj2 for the ith
study.
For i = 1;    ; k independent studies if ln ^i representing logarithm of
GOR be the observed eect size with variance vi and  i the underlying
population eect size. Then assuming  1 =  2 =    =  k =  0, a pooled
estimate of the treatment eect is given by
 ^0 =
P
i !iln ^iP
i !i
: (5.20)
Then the estimated variance of ln ^i with J dierent treatment and L-level
outcome categories can be found as
!^ 1i =
L 1X
l=1
JX
j=1
1
nij:^ijl(1  ^ijl) ; (5.21)
where nij: is the total count of jth group for the ith study, ^ijl = Xijl=nij:
is the maximum likelihood estimator (MLE) of ijl, Xijl is the count of the
lth category in the jth group for the ith study. Here each row of the J  L
table is modeled as an independent multinomial distribution.
For RCTs with two comparison groups the estimated variance, !^ 1i of the
ith study, becomes
!^ 1i =
L 1X
l=1
2X
j=1
1
nij:^ijl(1  ^ijl) : (5.22)
An approximate 100(1  )% CI for the GORs is given by the following
formula under normality assumption
exp[ln ^i  z=2! 1=2i ]; (5.23)
where z=2 is the 100(1  )% percentage point of a standard normal distri-
bution.
An estimator of the variance of ln ^0 is given by
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var(ln ^0) = 1=
kX
i=1
!i: (5.24)
Under normality assumption, an approximate 100(1  )% CI for the popu-
lation eect,  0, is given by
exp
24ln ^0  z=2
vuut1= kX
i=1
!i
35 (5.25)
for the meta analysis, where z=2 is the 100(1   )% percentage point of a
standard normal distribution.
5.4 Example
Here we consider the data (Table 5:1) for two variables income and job satis-
faction (JS), measured for the black males in U.S.A. The income variable has
four category levels in range and job satisfaction has four categories as well,
such as very dissatised (VD), little dissatised (LD), moderately satised
(MS), and very satised (VS).
Table 5.1: Contingency table for Job Satisfaction by Income
Job satisfaction
Income Very Little Moderately Very Total
(dollars) Dissatised Dissatised satised satised
<15,000 1 3 10 6 20
15,000-25,000 2 3 10 7 22
25,000-40,000 1 6 14 12 33
> 40,000 0 1 9 11 21
Source: 1996 General Social Survey, National Opinion Research Center,
USA.
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As the level of Income increases, responses on job satisfaction tend to
increase towards higher levels. Here, the GOR can be used as an eect
measure considering these two variables as concordant and discordant pairs.
Following this example, we generate data for ve studies using simulation
techniques under independent multinomial distribution for meta-analysis.
The data is presented in Table 5:2. This data has four groups in the row
variable and four categories in the column variable for each study. The last
two columns of the table contain the estimated GORs and weights for the
ve studies. Meta-analysis using these GORs is found to be 1:30 with CI
(0:16; 10:91).
Figure 1 shows the forest plot for the ve simulated studies. The solid
horizontal lines represent the 95% CI for the ve studies and meta-analysis.
The dashed vertical line represents the pooled estimate from these ve stud-
ies. The heterogeneity statistic Q = 0:004, df = 4, p-value = 0:99 suggests
that these studies are homogeneous. The I2 statistic = 0%[0%; 0%] also
indicates the homogeneity of these simulated studies.
5.5 Summary
The main contribution of this chapter is that we presented three dierent
meta-analysis methods for continuous outcomes. The rst method is appli-
cable when both the variables in a J  L contingency table are continuous.
That is, the outcome categories and the treatment categories are both contin-
uous. The second method is suitable when the multilevel outcome categories
are continuous and there are two comparison groups. The third method is
applicable when there are multiple outcome categories observed for a variable
that is inherently continuous with two or more comparison groups.
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Figure 5.1: Forest plot from simulated data using GOR
The rst and the third method used GOR as an eect measure while
the second method employed MD as an eect measure. Although the rst
situation is not very common in meta-analysis of RCTs, GOR is being used
for long time in such situation in psychology, education and ophthalmology.
However, the mathematical formulation is moderately complex. The other
two methods are simple and straightforward. Using MD and GOR, we can
estimate the eect sizes in two dierent scenarios. We trust these methods
will facilitate conducting more meta-analyses with continuous outcomes.
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Table 5.2: Five simulated studies
JS
Study Income VD LD MS VS Total GOR Weight
(dollars)
Study 1 <15,000 1 6 5 8 20 1.34 0.17
15,000-25,000 2 4 12 4 22
25,000-40,000 1 8 8 16 33
> 40,000 1 2 7 11 21
Study 2 <15,000 2 6 4 8 20 1.36 0.19
15,000-25,000 2 5 10 5 22
25,000-40,000 1 9 8 15 33
> 40,000 1 3 6 11 21
Study 3 <15,000 1 7 4 8 20 1.24 0.18
15,000-25,000 2 3 12 5 22
25,000-40,000 1 9 9 14 33
> 40,000 1 4 5 11 21
Study 4 <15,000 1 8 8 3 20 1.39 0.18
15,000-25,000 2 4 11 5 22
25,000-40,000 1 11 9 12 33
> 40,000 1 4 7 9 21
Study 5 <15,000 1 6 8 5 20 1.12 0.12
15,000-25,000 3 5 5 9 22
25,000-40,000 1 9 7 16 33
> 40,000 0 5 6 10 21
Meta-analysis=1.30 (0.16, 10.91)
Heterogeneity tests:
Q = 0:004, df = 4, p = 0:99
I2 = 0%[0%; 0%].
Chapter 6
Conclusion and Future Work
In this study, we considered the data from RCTs with multilevel ordinal cat-
egorical outcomes in meta-analysis. We aimed at estimating the eect sizes
without any loss of information by merging or splitting the J  L contin-
gency table into 2  2 tables. We employed GOR as an eect measure for
meta-analysis with ordinal outcome categories. GOR has the advantages of
estimating the eect sizes not only with RCTs of two comparison groups but
also any number of comparison groups and outcome categories.
Meta-analysis for ordinal outcomes
We developed a meta-analysis method for multilevel ordinal categorical out-
comes under independent multinomial distribution approach. The proposed
meta-analysis method is much easier than other methods and provide more
realistic results. More importantly, the proposed method estimates the ef-
fect sizes without merging categories and is free from any model assumption.
These properties lead the proposed method preferable and more realistic than
the existing methods for multilevel ordinal categorical outcomes.
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Heterogeneous ordinal outcomes
Heterogeneity is one of the most problematic aspects in meta-analysis. Sta-
tistical agreement of results is under serious question in the presence of het-
erogeneity. In this study, we have developed a QEBM using GOR for het-
erogeneous ordinal categorical outcomes. This method provides a remedy to
the issue of heterogeneity for ordinal categorical data in meta-analysis. The
QEBM identies the extreme study along with the Dixon's test of outliers.
This method also improves the meta-analysis using the predicted GOR tak-
ing into account the heterogeneity in the data set. The use of the predicted
GOR improves the meta-analysis sharply in terms of shrinking the CIs of
the study eects towards the pooled study eect. The proposed method
demonstrates a methodology for trustworthy meta-analysis with heteroge-
neous ordinal categorical outcomes.
GOR for binary outcomes
We have presented a meta-analysis method for binary outcomes using GOR
under both the xed and random eects models. A sample size weight
method for binary outcomes using ORG is also covered. We have applied
GOR, ORG for binary outcomes and compared results obtained with the
methods using ordinary OR. It is observed that the meta-analysis estimates
and their associated CIs under both FEM and REMs using GOR are ex-
actly the same as that of using OR under FEM and REMs respectively. It
is observed that the weights computed from the variance estimate of the in-
dividual GORs are the same with that of the ORs. Therefore, this study
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suggests that GOR can also be used for binary outcomes as eciently as
OR in meta-analysis. The sample size weight method have produced a lower
meta-analysis estimate as compared to other methods. However, a well de-
ned variance estimate for pooled ORG is not available.
Methods for continuous outcomes
We have also presented three methods for multilevel continuous outcomes in
meta-analysis in this thesis. The rst method is applicable when both the
variables are continuous in multilevel outcomes and comparison groups. The
second method is useful only when the multilevel continuous outcomes are
observed in RCTs with two comparison groups. The third method is for mul-
tilevel continuous outcomes when those are made ordinal from two or more
comparison groups. While the second method uses MD as an eect measure,
the rst and third method employ GOR as an eect measure. Although the
rst method is moderately complex, the other two methods are simple and
straightforward. We trust these methods will contribute widely conducting
more meta-analyses with continuous outcomes.
Challenges and future work
This study analyses outcome data in meta-analysis that occur in multilevel
ordinal categories. As in most cases the ordinal outcomes are naturally in
ascending or descending orders, it makes our study table setting easier for the
computation of the GOR as an eect measure. Because GOR is dened as
the proportion of concordant and discordant pairs, we need to set the study
table in such a way that as the level of outcome variable in the columns
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increases, so does the comparison groups in the rows in terms of severity or
vice versa.
Meta-analysis with more than two outcomes has not been carried out as
frequently as with binary outcomes. As a result, we have found insucient
data in the literature. In particular, we did not nd a set of studies with
signicant heterogeneity in these situations. Therefore, we used simulated
data along with the real data sets available.
Future research can be carried out using GOR under quality eects model
(Doi SA et al., 2011) for heterogeneous ordinal outcomes. GOR can also be
used under Bayesian meta-analysis of ordinal categorical data. However, the
challenges remain regarding the availability of the quality scores from studies
using GOR and development of softwares for computational purpose. We will
endeavour to resolve these challenges in our future work.
Agresti, A. (1980), `Generalised odds ratios for ordinal data', Biometrics, 36,
59  67.
Agresti, A. (2002), Categorical Data Analysis, Second Edition, Hoboken, New
Jersey. John Wiley & Sons, Inc.
Agresti, A. (2010), Analysis of Ordinal Categorical Data, 2nd Edition, Hoboken,
New Jersey. John Wiley & Sons, Inc.
Bancroft, T. A. (1944), `On biases in estimation due to the use of preliminary
test of signicance', Ann. Math. Stat., 15, 190  194.
Beecher, H. K. (1995), `The powerful placebo', J. Am. Medical Assoc., 159,
1602  1606.
Begg, C. B., and Mazumdar, M. (1994), `Operating characteristics of a rank
correlation test for publication bias', Biometrics, 50, 1088  1101.
Borenstein, M., Hedges, L. V., Higgins, J. P. T. and Rothstein, H. R. (2009),
Introduction to Meta-Analysis, First Edition, United Kingdom, John Wiley
CHAPTER 6. CONCLUSION AND FUTURE WORK 88
& Sons Ltd.
Casella, G. (1985), `An introduction to empirical Bayes data analysis', J. Am.
Stat. Assoc., 39, 83  87.
Chalmers, T. C., Matta, .J., Smith, H. Jr., and Kunzler, A. M. (1977), `Evidence
favoring the use of anticoagulants in the hospital phase of acute myocardial
infarction', New Engl. J. Med., 297, 1091  6.
Corneld, J. (1951), `A method of estimating comparative rates from clinical
data; applications to cancer of the lung, breast, and cervix', J Natl Cancer
Inst, 11(6), 1269  75.
Curtin, F., Altman, G. D. and Elbourne, D. (2002), `Meta-analysis combining
parallel and cross-over clinical trials. I: Continuous outcomes', Statistics in
Medicine, 21, 2131  2144.
Dale, J. R. (1984), `Local vs global association for bivariate ordered responses',
Biometrika, 71, 507  514.
DerSimonian, R. and Laird, N. (1986), `Meta-analysis in clinical trials', Control
Clin Trials, 7, 177  88.
Dickersin, K. and Berlin, J. A. (1992), `Meta-analysis: state-of-the-science', Epi-
demil. Rev., 14, 154  76.
Dixon, W. J. (1950), `Analysis of Extreme values', Ann. Math. Stat., 21, 488 
506.
Doi, S. A., Barendregt, J. J., and Mozurkewich, E. L. (2011), `Meta-analysis of
heterogeneous clinical trials: An empirical example', Contemporary Clinical
Trials, 32(2), 288  98.
Duval, S. and Tweedie, R. (2000), `Trim and ll: A simple funnel plot based
method of testing and adjusting for publication bias in meta-analysis', Bio-
metrics, 56(2), 455  463.
Edwardes, M. D. and Baltzan, M. (2000), `The generalization of the odds ratio,
CHAPTER 6. CONCLUSION AND FUTURE WORK 89
risk ratio and risk dierence to r  k tables', Statistics in Medicine, 19,
1901  1914.
Edwards, A. W. F. (1963), `The measure of association in a 22 table', Journal
of the Royal Statistical Society, 126(1), 109  114.
Efron, B. (1995), `A statistical century', R. Stat. Soc. News, 22, 1  2.
Efron, B. (1996), `Empirical Bayes methods for combining likelihoods', J. Am.
Stat. Assoc., 91, 538  50.
Efron, B. and Morris, C. N. (1973), `Stein's estimation rule and its competitors-
an empirical Bayes approach', Sci. Am., 236, 119  127.
Efron, B. and Morris, C. N. (1977), `Stein's paradox in Statistics', J. Am. Stat.
Assoc., 68, 117  130.
Emerson, J. D. (1994), `Combining estimates of the odds-ratio: the state of the
art', Stat. Methods Med. Res., 3, 157  178.
Fleiss, J. L. (1993), `The statistical basis of meta-analysis', Stat. Methods Med.,
2, 121  145.
Fleiss, J. L. (1994), `Measures of eect size for categorical data. In: Cooper, H.,
Hedges, L. V., (editors)', The Handbook of Research Synthesis, New York:
Russel Sage Foundation; 245  60.
Galbraith, R. F. (1988), `A note on graphical presentation of estimated odds
ratios from several clinical trials'. Statistics in Medicine, 7, 889  894.
Greenland, S. (1987), `Quantitative methods in the review of epidemiologic lit-
erature', Epidemio. Rev., 9, 1  30.
Gupta, A. K. and Saleh, A. K. Md. E. (1997), `Estimating odds-ratio: Homo-
geneous constraints', J. Itel. Stat. Soc., 6, 67  81.
Han, C. P., Bancroft, T. A. (1968), `On pooling means when variance is known',
J. Am. Stat. Assoc., 63, 1333  1342.
Hedges, L. V. and Olkin, I. (1985), Statistical Methods for Meta-Analysis, San
CHAPTER 6. CONCLUSION AND FUTURE WORK 90
Diego: Academic Press Inc.
Higgins, J. P. T and Thompson S. G. (2002), `Quantifying heterogeneity in a
meta-analysis', Statistics in Medicine, 21, 1539  1558.
Hossain, M. B. and Khan, S. (2011), `Meta-analysis for ordinal categorical out-
comes', Submitted to Statistics in Medicine.
Hozo, S. P., Djulbegovic, B. and Hozo, I. (2005), `Estimating the mean and
variance from the median, range, and the size of a sample', BMC Med Res
Methodolo., 5(13). doi: 10:1186=1471  2288  5  13.
Hwang, J. T. and Casella, G. (1982), `Minimax condence sets for the mean of
a multivariate normal distribution', Ann. Stat., 10, 868  881.
Judge, G. G., and Bock, M. E. (1978), The Statistical Implications of Pre-test
and Stein-rule Estimators in Econometrics, North-Holland, Amsterdam.
Kendall, M. and Gibbons, J. D. (1990), Rank Correlation Methods. First Edition,
New York: Oxford University Press.
Khan, S. and Hoque, Z. (2002), `James-Stein estimators for the mean vector of
a multivariate normal population based on independent samples from two
normal populations with common covariance structure', Pakistan Journal of
Statistics, Special Issue, 18(3), 359  381.
Khan, S. (2003), `Estimation of the Parameters of two Parallel Regression Lines
Under Uncertain Prior Information', Biometrical Journal, 44, 73  90.
Khan, S. (2008), `Shrinkage Estimators of Intercept Parameters of Two Simple
Regression Models with Suspected Equal Slopes', Communications in Statis-
tics - Theory and Methods, 37, 247  260.
L'Abbe, K. A., Detsky, A.S., and O'Rourke, K. (1987), `Meta-analysis in clinical
research', Annals of Internal Medicine, 107, 224  233.
Laird, N., Fitzmaurice, G. and Ding, X. (2010), Comments on `Empirical vs
natural weighting in random eects meta-analysis', Statistics in Medicine ,
CHAPTER 6. CONCLUSION AND FUTURE WORK 91
29(12), 1266  1267.
Lehmann, E. L. (1975), Nonparametrics: Statistical Methods Based on Ranks.
San Francisco: Holden-Day.
Lewis, S. and Clarke, M. (2001), `Forest plots: trying to see the wood and the
trees', BMJ, 322, 1479  1480.
Light, R. J. and Pillemar, D. B. (1984), Summing Up: The Science of Reviewing
Research, Cambridge, MA: Harvard University Press.
Mann, C. (1990), `Meta-analysis in breech', Science, 249, 476  490.
Mantel, N. and Haenszel, W. (1959), `Statistical aspects of the analysis of data
from retrospective studies of disease', J. Nat. Cancer Inst., 22, 719  748.
Mantel, N. (1963), `Chi-square tests with one degree of freedom: extensions of
the Mantel-Haenszel procedure', J. Am. Statist. Assoc., 58, 690  700.
McCullagh, P. (1980), `Regression models for ordinal data', J. R. Statist. Soc,
B, 42(2), 109  142.
Memon, M. A., Subramanya, M. S., Khan, S., Hossain, M. B., Osland, E., and
Memon, B. (2011), `Meta-analysis of D1 versus D2 gastrectomy for gastric
adenocarcinoma', Annals of Surgery, 253(5), 900  911.
Morris, C. N. (1983), Parameter Empirical Bayes Condence Intervals, Scientic
Inference, Data Analysis and Robustness. New York: Academic Press Inc.,
pp. 22  50.
Morris, C. N. (1992), `Hierarchical models for combining information and for
meta-analysis', Bayesian Statistics, 4, 321  44.
Mosteller, F. (1968), `Association and estimation in contingency tables', Journal
of the American Statistical Association, 63(321), 1  28.
Noether, G. E. (1967), Elements of Non-parametric Statistics. New York, Lon-
don, Sydney: John Wiley and Sons, Inc. pp. 70  83.
Pearson, K. (1904), Report on certain enteric fever inoculation statistics. B.
CHAPTER 6. CONCLUSION AND FUTURE WORK 92
Med J., 3, 1243  6.
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R. and Howard, S. V.
(1977), `Design and analysis of randomized clinical trials requiring prolonged
observation of each patient. II. analysis and examples', Br. J. Cancer, 35,
1  39.
Peto, R. (1987), `Why do we need systematic overview of randomized trials?',
Statistics in Medicine, 6, 233  240.
Qizilbash N. Whitehead. A, Higgins. J, Wilcock. G, Schneider. L and Farlow,
M. (1998), `Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis
of the Tacrine Trials', Journal of the American Medical Association, 280,
1777-1782.
Raudenbush, S. W. and Bryk, A. S. (1985), `Empirical Bayes meta-analysis', J.
Educ. Statist, 10, 75  98.
Raudenbush, S. W. (1994), Random eects models. In: Cooper, H., Hedges,
L.V., (editors). The Handbook of Research Synthesis. New York: Russell
Sage Foundation. 301  22.
Rosenthal, R. (1994), The Handbook of Research Synthesis, New York: Russell
Sage Foundation, pp. 231  244.
Rucker, G., Schwarzer, G., Carpenter, J. and Schumacher, M. (2010), Com-
ments on `Empirical vs natural weighting in random eects meta-analysis',
29, 2963  2966.
Saleh, A. K. Md. E., Hassanein, K. M., Hassanein, R. S., and Kim, H. M.
(2006), `Quasi-empirical Bayes methodology for improving meta-analysis',
Journal of Biopharmaceutical Statistics, 16, 77  90.
Saleh, A. K. Md. E. (2006), Theory of Preliminary Test and Stein-type Estima-
tion with Applications, Hoboken, New Jersey. John Wiley & Sons, Inc.
Schlesselman, J. and Stolley, P. (1982), Case-control Studies. Design, Conduct,
CHAPTER 6. CONCLUSION AND FUTURE WORK 93
Analysis, New York: Oxford University Press.
Schork, M. A. and Remington, R. D. (2000), Statistics with Applications to the
Biological and Health Sciences, Upper Saddle River, New Jersey: Prentice
Hall.
Senn, S. (2007), `Trying to be precise about vagueness', Statistics in Medicine,
26(7), 1417  30.
Shuster, J. J. (2010), `Empirical vs natural weighting in random eects meta-
analysis', Statistics in Medicine, 29, 1259  1265.
Spector, T. D. and Thompson, S. G. (1991), `Research methods in epidemiology
5. The potential and limitation of meta-analysis', J. Epidemiol. Comm.
Hlth., 45, 89  92.
Stein, C. (1956), Inadmissibility of the usual estimator of mean of a multivariate
normal distribution, Proceedings 3rd Berkeley Symposium on Mathematical
Statistics and Probability, pp. 197  206.
Stijnen, T. and Van Houwelingen, J. C. (1990), `Empirical Bayes methods in
clinical trials meta-analysis', Biometrical J., 32, 335  46.
Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A. and Song, F. (2000),
Methods for Meta-Analysis in Medical Research, West Sussex, PO191UD,
England: John Wiley & Sons, Ltd.
Thompson, S. G. and Higgins, J. P. T. (2010), Comments on `Empirical vs
natural weighting in random eects meta-analysis', Statistics in Medicine,
29(12), 1270  1271.
Thompson, S. G. and Pocock, S. J. (1987), `Can Meta-analysis be trusted?',
Lancet, 338, 1127  1130.
Van Houwelingen, H. C. and Stijnen, T. (1993), `Monotone empirical Bayes
estimators based on more informative samples', J. Am. Statist. Assoc., 88,
1438  43.
CHAPTER 6. CONCLUSION AND FUTURE WORK 94
Waksman, J. A. (2010), Comments on `Empirical vs natural weighting in random
eects meta-analysis', Statistics in Medicine, 29(12), 1268  1269.
Whitehead, A. and Jones N. M. B. (1994), `A meta-analysis of clinical trials in-
volving dierent classications of response into ordered categories', Statistics
in Medicine, 13, 2503  2515.
Whitehead, A., Omar, R. Z., Higgins, J. P. T., Savaluny, E., Turner, R. M. and
Thompson, S. G. (2001), `Meta-analysis of ordinal outcomes using individual
patient data', Statistics in Medicine, 20, 2243  2260.
Woolf, B. (1955), `On estimating the relation between blood group and disease',
Ann. Hum. Genet., 19, 251  253.
Yates, F. and Cochran, W.G. (1938). The analysis of groups of experiments. J.
Agricultural Sci., 28, 55  80.
Yusuf, S., Peto, R., Lewis, J., Collins, R. and Sleight, P. (1985). Beta blockade
during and after myocardial infarction: an overview of the randomised trials.
Progress in Cardiovascular Diseases, 27, 335  71.
Zhou, X. H. (1996), `Empirical Bayes combination of estimated ares under ROC
curves using estimating equations', Med. Decision Making, 16, 24-8.
Appendix A
A.1 Delta Method
Suppose that ^0 = (^1; ^2; : : : ; ^S) asymptotically follows the multivariate
normal distribution with mean 0 = (1; 2; : : : ; S) and covariance matrix
=n and further that g(x) has a continuous non-zero dierential g(x)/xi at
x= . Dene g=xjx= as the vector (g(x)/x1; g(x)/x2, : : :, g(x)/xS)0
evaluated at x = . Then,
p
n(g(^)-g()) asymptotically follows the mul-
tivariate normal distribution with mean 0 and variance-covariance matrix
(g=x)0jx= (g=x)jx=. For example, if a random vector (Y1; Y2; : : : ; YS)0
follows a multinomial distribution with parameters n and = (1; 2; : : : ; S)
0
then, by the CLT, for large n the random vector (^1; ^2; : : : ; ^S)
0 asymptoti-
cally has the multivariate normal distribution with mean = (1; 2,: : : ; S)
0
and co-variance matrix [diag()-0]=n, where ^i = Yi=n, and diag() is a
diagonal matrix with diagonal elements equal to i. Thus using the delta
method, we may claim that
p
n(g(^)-g()) asymptotically follows the mul-
tivariate normal distribution with mean 0 and variance
P
i i(g=xi)
2jx= 
(
P
i i(g=xi)jx=)2.
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A.2 The Proportional Hazard Model
The hazard function (t;x) is dened to be the instantaneous failure proba-
bility at time t conditional on survival up to time t. The proportional hazard
model for an individual with covariate x is given by
(t;x) = 0(t) exp( Tx); (A.1)
where 0(t) is the hazard function at x=0 and  is a vector of unknown
parameters. This model can be used in survival analysis (Cox, 1972). Here
the survival function S(t;x), the probability of surviving beyond time t given
the co-variate x, satises
  log fS(t;x)g = 0(t) exp( Tx); (A.2)
where 0(t)=
R t
0 (s)ds. So for any two individuals with covariates x1 and
x2 respectively the survival function satisfy
log S(t; x1)=log fS(t; x2)g = expfT (x2   x1)g: (A.3)
That is, the ratio of log survival functions, like the ratio of the hazard func-
tions depends only on the dierence between the covariate values x2   x1
and is constant for all t. For discrete data, the proportional hazards model
(A.2) becomes (McCullagh, 1980)
  log f1  j(x)g = exp(j   Tx); (A.4)
where 1 j(x) is the probability of survival beyond category j given covariate
values x. Logarithm of the above equation gives us a more appropriate linear
structure analogous to the linear logistic model as follows
log [ log f1  j(x)g] = j   Tx; (A.5)
the transformation to linearity being called the complementary log-log trans-
form.
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A.3 Ordered Logistic Regression
The ordered logistic regression model is an extension of the binary model.
The model is frequently employed with three or more ordered levels. The
foremost ordered logistic model is the proportional odds model. The pro-
portional odds model assumes that the model coecients for each level of
response are equal or slopes can be parameterized for any of the binomial
links e.g., logit or logistic, the probit, complementary loglog, loglog and Cau-
chit as found in generalised linear models.
A.4 Odds Ratio
The odds ratio (OR) is dened as the ratio of two odds of interest and is
calculated from Table A.1 as
Table A.1: Data of a single RCT
Intervention Success/Alive Failure/Dead
New treatment a b
Control c d
OR =
(a=n)=(b=n)
(c=n)=(d=n)
=
ad
bc
; (A.6)
where a, b, c, and d are the cell frequencies of the four cells in a RCT setting
for a 2  2 table. For desirable outcomes OR greater than one indicates
improvement by the new treatment while an OR less than one means the
new treatment is less eective. For undesirable outcomes the converse is true.
The following large sample variance (Fleiss, 1993) of the log OR is commonly
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used for the purpose of pooling in meta-analysis and for computing the CI.
var(ln OR) =
1
a
+
1
b
+
1
c
+
1
d
: (A.7)
For zero cell count problem, it is recommended adding 0:5 to each cell of all
the studies of 2 2 tables. This also reduces the bias caused by one or more
small cells in the study table. Under the normality assumption of the ln OR,
a 95% CI for ln OR can be found as
exp[ln OR 1:96
q
var(ln OR)]: (A.8)
A.5 Relative Risk
The relative risk or risk ratio (RR) is dened as the probability of an event
in the treatment group divided by the probability of an event in the control
group (Table A.1) as
RR =
a=(a+ b)
c=(c+ d)
: (A.9)
Useful variance expression of the log RR can be found as
var(ln RR) =
1
a
  1
a+ b
+
1
c
  1
c+ d
: (A.10)
A 95% CI for ln RR can be calculated under the assumption of normality as
exp[ln RR 1:96
q
var(ln RR)]: (A.11)
There are debates on the choice of binary eect measures between OR and
RR. Some researchers prefer OR as an eect measure than RR because OR
can be estimated and interpreted for RCTs and case-control study reasonably
for rare outcomes. Moreover, some study designs select subjects on the basis
of outcome rather than the treatment type (case-control study). RR can not
be used for this study design.
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A.6 Risk Dierence
Apart from the OR and RR that measure the association between treatment
and outcome, risk dierence (RD) provides an indication of the impact of
the treatment or exposure. The RD is dened for a 22 table simply as risk
in the experimental group minus risk in the control group and is calculated
as
RD = a=(a+ b)  c=(c+ d): (A.12)
The variance estimate of RD can be found (Fleiss, 1993) as
var (RD) =
p1(1  p1)
n1
+
p2(1  p2)
n2
; (A.13)
where p1 = a=(a + b), p2 = c=(c + d), n1 = a + b and n2 = c + d. A 95% CI
for RD can be computed as
RD
q
var(RD): (A.14)
A.7 Arcsine Dierence
The arcsine dierence (AS) is dened as
AS = arcsin
s
a
a+ b
  arcsin
s
c
c+ d
: (A.15)
The AS is a measure rarely used in medical science which handles zero fre-
quencies naturally. The asymptotic variance of AS which does not depend
on the event of probability is given as
var(AS) =
1
4(a+ b)
+
1
4(c+ d)
: (A.16)
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A.8 Continuity Corrections for Zero Cells
Consider the cells of binary data for the ith study in the following table as:
Study i Event No Event Total
Treatment ai bi ai + bi
Control ci di ci + di
When any of the four cells is zero, we add 0.5 to all cells of the contingency
table. This is otherwise called the Woolf-Haldane correction for the odds
ratio (Schlesselman, 1982). Alternatively, statistical software Rmeta adds
0:5 to all the cells of all the studies involved in the meta-analysis. As a
result, there is an increase of 1 subject in each row involved in the analysis.
In our analysis with J  L contingency table, we add 1=L to each cell with
zero frequency. For example, in a 23 contingency table we add 1=3 to each
cell and for a 24 contingency table, we add 1=4 and so on. Therefore, there
is an increase of one subject in each group involved in the analysis as in the
case of OR.
A.9 Peto's Method
This method was rst introduced by Peto et al. (1977) and later more elabo-
rately by Yusuf et al. (1987). This method is considered as a break through
in the eld of meta-analysis. Although this method may produce serious un-
der estimates (Fleiss, 1994) for large treatment or exposure eects or in the
meta-analysis of epidemiology (Spector and Thompson, 1991), it is unlikely
to be a problem in clinical trials. For the working formula, let us dene the
following:
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ni = number of subjects in the ith trial
nti = number of subjects in the new treatment group
di = total number of events from both treatment and control groups
Oi = observed number of events in the treatment group
Ei = (nti  di)=ni = expected number of subjects in the treatment group.
For k studies, i = 1; 2; : : : ; k, the pooled estimate of the OR under this
method is calculated as
TPeto(OR) = exp
"
kX
i=1
(Oi   Ei)=
kX
i=1
vi
#
; (A.17)
where vi = Ei[(ni   nti)=ni][(ni   di)=(ni   1)]. An approximate variance
estimate is given by
var(ln TPeto(OR)) =
 
kX
i=1
vi
!
: (A.18)
An asymmetric 100(1  )% CI is thus found as
exp
0@Pki=1(Oi   Ei) z=2
qPk
i=1 viPk
i=1 vi
1A ; (A.19)
where z=2 is the (1  =2)100 percentage point of a standard normal distri-
bution.
A.10 Mantel-Haenszel Method
The Mantel-Haenszel method also known as M-H method was rst described
by Mantel and Haenszel (1959) for combining ORs for stratied case-control
studies. This method is a xed eects model approach and could be used
for a variety of laboratory experiments (Mantel, 1963). In meta-analysis it is
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widely used considering each study as an individual stratum (Dickersin and
Belin, 1992). For the 22 table with ai, bi, ci and di, the four cell frequencies
and ni, the total number of subjects in the ith study, i = 1; : : : ; k, the pooled
estimate is calculated as
TMH(OR) =
Pk
i=1 aidi=niPk
i=1 bici=ni
: (A.20)
A variance estimate (Robin et al., 1986) for the log TMH(OR) can be computed
as
v
MH(lnOR) =
Pk
i=1 PiRi
2
Pk
i=1Ri
 + Pki=1(PiSi +QiRi)
2
Pk
i=1Ri
 Pk
i=1 Si
 + Pki=1(QiSi)
2
Pk
i=1 Si
 ; (A.21)
where Pi = (ai+ di)=ni, Qi = (bi+ ci)=ni, Ri = (aidi)=ni, and Si = (bici)=ni.
A 100(1  )% CI for the pooled OR,  can be found as
exp
h
ln TMH(OR)  z=2(vMH(lnOR))1=2
i
; (A.22)
where z=2 is the (1  =2)100 percentage point of a standard normal distri-
bution.
A.11 Estimating Mean and SD from Median,
Range and Sample Sizes
Hozo et al. (2005) produced an excellent work on estimating the mean and
standard deviation from the median, range and sample size. The sample
mean, x can be used to estimate the population mean as
x =
a+ 2m+ b
4
; (A.23)
where m is the median and a and b are the low and high end of the range
respectively. The variance can be estimated using the formula as
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S2  1
12
 
(a  2m+ b)2
4
+ (b  a)2
!
: (A.24)
In addition, the well estimators of standard deviation Range/4 for a normal
distribution and Range/6 for any random distribution also useful in meta-
analysis. The best estimating formulae for mean and standard deviation (sd)
depending on the sample sizes for any unknown distribution are listed below:
Table A.2: The best estimating formulas for mean and sd
Sample size n  15 15< n  25 25 < n  70 70 < n
Estimate mean Formula A.23 Formula A.23 Median Median
Estimate sd Formula A.24 Range/4 Range/4 Range/6
A.12 Kendall's tau
Suppose we take two members xi and xj at random from a continuous pop-
ulation. Then we may consider the probability xi < xj and xi > xj. Again
let us take two members xi, yi and xj, yj from a bivariate continuous popu-
lation. Then we may consider the probabilities of concordance of type 1 as
the conditional probability that yi < yj given that xi < xj. That is,
c = Prob(yi < yjjxi < xj): (A.25)
and
1  c = Prob(yi > yjjxi < xj): (A.26)
The probability c represents a property of the population. Let us draw a
sample of n values at random from the bivariate population and arrange the
x values in ascending order of magnitude. Of the 1=2n(n   1) pairs of x
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values which we may choose for comparison, some have the corresponding
y values in ascending order and some do not. The number of those which
do divided by 1=2n(n   1) is clearly as estimator (unbiased) of c. If pc is
this proportion and qc=1  pc, then the Kendall's tau coecient () for this
example is
 = pc   qc = 2pc   1: (A.27)
Thus we could therefore dene  in terms of concordance and arrive at a
coecient which has an analogue in the continuous case.
A.13 Mann-Whitney U Statistic
The Mann-Whitney statistic U is obtained by ordering two samples (n1 +
n2) observations according to their magnitude and counting the number of
observations in sample II that precede each observation in sample I. For
comparing two distributions of independent continuous random variables U
can be written as
U = P^21=n1n2; (A.28)
where P^21 is the sample version of P21 = P (Y2 > Y1). The GOR ( ) for two
independent continuous random variables is written as
  = P (Y2 > Y1)=f1  P (Y2 > Y1)g: (A.29)
Therefore, the relationship between   and U can be written as
  =
U=n1n2
(n1n2   U)=n1n2 (A.30)
=
U
n1n2   U :
As a non-parametric approach the U statistic has the advantage that the
two sample under consideration may not necessarily have the same number
of observations.
Appendix B
B.1 R Code for Chapter 2
Listing B.1: R code for the GOR functions, weights, CIs, PGORs and CIs
# GOR functions for 2 5 contingency table
tr<  c(f11, f12, f13, f14, f15, n11)# f11 = count in cell (1, 1), f12 = count
in cell (1, 2) and so on
cl<  c(f21, f22, f23, f24, f25, n21)
e1<  cbind(tr, cl)
e<  t(e1)
n11<  e[1,6]
n21<  e[2,6]
p11<  e[1,1]/e[1,6]
p12<  e[1,2]/e[1,6]
p13<  e[1,3]/e[1,6]
p14<  e[1,4]/e[1,6]
p15<  e[1,5]/e[1,6]
p21<  e[2,1]/e[2,6]
p22<  e[2,2]/e[2,6]
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p23<  e[2,3]/e[2,6]
p24<  e[2,4]/e[2,6]
p25<  e[2,5]/e[2,6]
pc<  ((p11p22)+(p11p23)+(p11p24)+(p11p25)+(p12p23)+(p12p24)+
(p12p25) +(p13p24)+(p13p25)+(p14p25))
pd<  ((p12p21)+(p13p21)+(p13p22)+(p14p21)+(p14p22)+(p14p23)+
(p15p21) +(p15p22)+(p15p23)+(p15p24))
gi<  pc/pd
#Weight for the ith study
tr<  c(f11, f12, f13, f14, f15, n1)
cl<  c(f21, f22, f23, f24, f25, n2)
e1<  cbind(tr, cl)
e<  t(e1)
n1<  e[1,6]
n2<  e[2,6]
p11<  e[1,1]/e[1,6]
q11<-1-p11
p12<  e[1,2]/e[1,6]
q12<  1-p12
p13<  e[1,3]/e[1,6]
q13<  1-p13
p14<  e[1,4]/e[1,6]
q14<  1-p14
p21<  e[2,1]/e[2,6]
q21<  1-p21
p22<  e[2,2]/e[2,6]
q22<  1-p22
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p23<  e[2,3]/e[2,6]
q23<  1-p23
p24<  e[2,4]/e[2,6]
q24<  1-p24
w1i<  (1/(n1p11q11)+1/(n1p12q12)+1/(n1p13q13)+ 1/(n1p14q14)
+ 1/(n2p21q21)+1/(n2p22q22)+1/(n2p23q23)+1/(n2p24q24))
wi<  1/w1i; i=1, 2, : : :, k=5. # number of studies.
# pooling GOR
wi<  c(w1,w2,w3,w4,w5)
sei<  sqrt(1/wi)
g1<  log(gi)
t<  sum(g1*wi)/sum(wi).
#calculation of ci for individual GOR
ll<  format(exp(log(g) -1.96wi 1=2),digits=4)
ul<  format(exp(log(g) +1.96wi 1=2),digits=4)
ci<  data.frame(ll,ul)
#CI for pooled GOR
w<  sum(wi)
ll<  format(exp(log(t) -1.96w 1=2),digits=4)
ul<  format(exp(log(t) +1.96w 1=2),digits=4)
ci<  data.frame(ll,ul)
B.2 Sample Size Weight Method
Listing B.2: R code for sample size weights
# CI for ORG
selg1<  (2seg1)/((1  ga1)2)
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# selg<  SE(logORG)
ci1<  c(or1exp((-3.92seg1)/(1 (ga1)2)),or1exp((3.92seg1)/(1 (ga1)2)))
# weights
n1<  1st col total
n2<  2nd col total
n3<  3rd col total
n4<  4th col total
n5<  5th col total
ga<  gammas
seg<  standard error of gammas
se2<  seg2
tni<  n1n2/(n1+n2)+ n1n3/(n1+n3)+ n3n2/(n3+n2)
+ n1n4/(n1+n4)+n1n5/(n1+n5)+n4n2/(n4+n2)+ n5n2/(n5+n2)
+n3n4/(n3+n4)+n3n5/(n3+n5)+n4n5/(n4+n5)
# Pooling by Sample size weighting
ga<   gammas for the studies # easily obtainable from crosstab command
of SPSS
seg<   standard errors of gammas # easily obtainable from crosstab com-
mand of SPSS
se2<  seg2
tn2<  tni2
gb<  sum(tni*ga)/sum(tni)
ORb<  (1+gb)/(1-gb)
segb<  sqrt(sum(tn2se2))/sum(tni)
cip<  c(ORbexp((-3.92segb)/(1 (gb)2)),ORbexp((3.92segb)/(1 (gb)2)))
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B.3 R Code for Chapter 3
Listing B.3: R code for GORs, weights for three categories of tacrine trials
# GORs for 2 3 contingency tables
tr<  c(f11, f12, f13, Total)
cl<  c(f21, f22, f23, Total)
e1<  cbind(tr, cl)
e<  t(e1)
n11<  e[1,4]
n21<  e[2,4]
p11<  e[1,1]/e[1,4]
p12<  e[2,1]/e[2,4]
p13<  e[1,3]/e[1,4]
p21<  e[1,2]/e[1,4]
p22<  e[2,2]/e[2,4]
p23<  e[2,3]/e[2,4]
pc<  (p11*p22)+(p11*p23)+(p21*p23)
pd<  (p12*p21)+(p13*p12)+(p13*p22)
gi<  pc/pd
# Weights
p<  c(32,54,24,110)
t<  c(24,45,27,96)
e1<  cbind(p,t)
e<  t(e1)
n1<  e[1,4]
n2<  e[2,4]
p11<  e[1,1]/e[1,4]
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q11<  1-p11
p12<  e[1,2]/e[1,4]
q12<  1-p12
p21<  e[2,1]/e[2,4]
q21<  1-p21
p22<  e[2,2]/e[2,4]
q22<  1-p22
w1i<  1/(n1*p11*q11)+1/(n1*p12*q12)+1/(n2*p21*q21)+1/(n2*p22*q22)
wi<  1/w1i
# Calculation of ci for individual GOR for tacrine trials
g<   gor for the studies
wi<  weights
ll<  format(exp(log(g) -1.96*wi( 1=2)),digits=4)
ul<  format(exp(log(g) +1.96*wi( 1=2)),digits=4)
ci<  data.frame(ll,ul)
# pooling GOR
g2<  c(1.274390, 1.185958, 1.312500, 2.079957, 1.546875 )
g<  log(g2)
wi<  c(5.623291, 5.718636, 2.767237, 13.253025, 9.190350)
t<  sum(g*wi)/sum(wi)
pt<  exp(t)
# CI for pooled GOR
w<  sum(wi)
ll<  format(exp(log(1.583732) -1.96*w( 1=2)),digits=4)
ul<  format(exp(log(1.583732) +1.96*w(   1=2)),digits=4)
ci<  data.frame(ll,ul)
# calculation of PGOR
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g<  c(1.274390, 1.185958, 1.312500, 2.079957, 1.546875 )
df<  length(g)-1
w<  c(5.623291, 5.718636, 2.767237, 13.253025, 9.190350)
q2<  1.831287# value of the chi-square statistic
k<   1-((df-2)/q2)
pg<  log(1.583732)+k*(log(g)-log(1.583732))
g1<  exp(pg)
#CI for PGOR
wi<  c(5.623291, 5.718636, 2.767237, 13.253025, 9.190350)
ll<  format(exp(pg-1.96*wi( 1=2)),digits=4)
ul<  format(exp(pg+1.96*wi( 1=2)),digits=4)
cip<  data.frame(ll,ul)
#Standard chisquare test with logGOR
w<  c(5.623291, 5.718636, 2.767237, 13.253025, 9.190350)
t<  c(1.274390, 1.185958, 1.312500, 2.079957, 1.546875 )
T<  log(t)
T2<  T*T
T3<  w% %T
T4<  T3/sum(w)
T5<  T32
T6<  sum(wT2)
T7<  sum(w)
q<  T6-(T5/T7)
q2<  sum(w  ((T   T4)  2))
Q1<  sum(wT2)-(T5/T7)
# I2 for tacrine
Q<  1.831287
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df<  4
I2<  (Q-df)/Q  100
if Q>df+1 then
d1<  2df-1
q1<  2 Q
B<  0:5  (log(Q)-log(df))/(sqrt(q1)-sqrt(d1))
or
if Q <  df+1
p1<  3  (df   1)2
p2<  1/2*(df-1)*(1-(1/p1))
B<  sqrt(p2)
L<  exp(0.5*log(Q/df)-1.96*B)
U<  exp(0.5*log(Q/df)+1.96*B)
LL<  (L2   1)=L2  100
UL<  (U2   1)=U2  100
#95% CI for GOR tacrine trials
x<  1.58
y<  1
plot(x,y,xlim=c(-1.5,6),ylim=c(-1,7),xaxt=\n",
yaxt=\n",frame.plot = NULL,cex=1)
segments(0, 0, 0, 7, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 0, 6, 0, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(1, 0, 1, 7, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(1.58, 0, 1.58, 7, col = \black", lty = 5, lwd = par(\lwd"))
x5<  c(0.558, 2.91)
y5<  c(6,6)
lines(x5,y5,ty=\l")
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x6<  c(0.523, 2.69)
y6<  c(5,5)
lines(x6,y6,ty=\l")
x7<  c(0.404, 4.26)
y7<  c(4,4)
lines(x7,y7,ty=\l")
x8<  c(1.214, 3.56)
y8<  c(3,3)
lines(x8,y8,ty=\l")
x9<  c(0.81, 2.95)
y9<  c(2,2)
lines(x9,y9,ty=\l")
x10<  c(1.145,2.19)
y10<  c(1,1)
lines(x10,y10,ty=\l")
text(0, 6, labels=\Study 1", pos=2,adj = c(0,0), cex = .8)
text(0, 5, labels=\Study 2", pos=2,adj = c(0,0), cex = .8)
text(0, 4, labels=\Study 3", pos=2,adj = c(0,0), cex = .8)
text(0, 3, labels=\Study 4", pos=2,adj = c(0,0), cex = .8)
text(0, 2, labels=\Study 5", pos=2,adj = c(0,0), cex = .8)
text(0, 1, labels=\Meta-analysis",adj = c(0,0), pos=2, cex =.8)
#PGOR
x5<  c(0.707, 3.69)
y5<  c(5.75,5.75)
lines(x5,y5,ty=\l",col=\black",lty=5)
x6<  c(0.717, 3.69)
y6<  c(4.75,4.75)
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lines(x6,y6,ty=\l",col=\black",lty=5)
x7<  c(0.496, 5.23)
y7<  c(3.75,3.75)
lines(x7,y7,ty=\l",col=\black",lty=5)
x8<  c(0.901, 2.65)
y8<  c(2.75,2.75)
lines(x8,y8,ty=\l",col=\black",lty=5)
x9<  c(0.831, 3.03)
y9<  c(1.75,1.75)
lines(x9,y9,ty=\l",col=\black",lty=5)
text(1.58, 0, labels=\1.58", pos=1, adj = c(0,0),cex = .8)
text(0, 0, labels=\0", pos=1, adj = c(0,0),cex = .8)
text(1, 0, labels=\1", pos=1, adj = c(0,0),cex = .8)
#text(2, 0, labels=\2", pos=1, adj = c(0,0),cex = .8)
text(4, 0, labels=\4", pos=1, adj = c(0,0),cex = .8)
text(6, 0, labels=\6", pos=1, adj = c(0,0),cex = .8)
text(2.8, -.71, labels=\Generalised Odds Ratio (log-scale)", pos=1, adj =
c(2.50,-1),cex = .8)
points(6,0,pch=\'",cex =1)
points(4,0,pch=\'",cex =1)
B.4 Misoprostol Trials
Listing B.4: R code for GORs, weights, CI, PGORs, Ln and I
2
# GORs for 2 3 contingency table
tr<  c(f11, f12, f13, n11)
cl<  c(f21, f22, f23, n21)
e1<  cbind(nc,ca)
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e<  t(e1)
n11<  e[1,4]
n21<  e[2,4]
p11<  e[1,1]/e[1,4]
p12<  e[2,1]/e[2,4]
p13<  e[1,3]/e[1,4]
p21<  e[1,2]/e[1,4]
p22<  e[2,2]/e[2,4]
p23<  e[2,3]/e[2,4]
pc<  (p11*p22)+(p11*p23)+(p21*p23)
pd<  (p12*p21)+(p13*p12)+(p13*p22)
gi<-pc/pd, i = 1; 2; : : : ; 10.
# weights
x11<  f11
x12<  f12
x13<  f13
x21<  f21
x22<  f22
x23<  f23
n1<  1st column total
n2<  2nd column total
p11<  x11/n1
q11<  1-p11
p12<  x12/n1
q12<  1-p12
p21<  x21/n2
q21<  1-p21
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p22<  x22/n2
q22<  1-p22
w1i<  1/(n1*p11*q11)+1/(n1*p12*q12)+1/(n2*p21*q21)+
1/(n2*p22*q22)
w1<  1/w1i, i = 1; 2; : : : ; 10.
# Pooling GOR
g<  c(28.526316, 68.645161, 5.450704, 23.123711, 15.714286, 2.990099, 3.126642
, 3.987988, 8.307692, 1.757374)
sn<  log(g)
w<  c(1.0858756, 0.2918908, 1.7150532, 0.2874851, 0.1986054, 3.1277129,
3.3480683, 0.5934123, 0.7058769, 4.2951792)
t<  sum(sn*w)/sum(w)
pt<  exp(t)
# Calculation of the Ln statistic
sn<  c(28.526316, 68.645161, 5.450704, 23.123711, 15.714286, 2.990099,
3.126642 , 3.987988, 8.307692, 1.757374)
w<  c(1.0858756, 0.2918908, 1.7150532, 0.2874851, 0.1986054, 3.1277129,
3.3480683, 0.5934123, 0.7058769, 4.2951792)
wd<  diag(w)
pi<  log(sn)
s0<  rep(log(3.878293),10)
x<  (pi-s0)
p2<  t(x)% %wd
ln<  p2% %x
p3<  (t(x)%*%wd%*%x)
# CI for individual GOR for misoprostol trials
g<  c(28.526316, 68.645161, 5.450704, 23.123711, 15.714286, 2.990099, 3.126642
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, 3.987988, 8.307692, 1.757374)
wi<  c(1.0858756, 0.2918908, 1.7150532, 0.2874851, 0.1986054, 3.1277129,
3.3480683, 0.5934123, 0.7058769, 4.2951792)
ll<  format(exp(log(g) -1.96*wi( 1=2)),digits=4)
ul<  format(exp(log(g) +1.96*wi( 1=2)),digits=4)
ci<  data.frame(ll,ul)
# ci for pooled GOR
w<  sum(wi)
ll<  format(exp(log(3.878293) -1.96*w( 1=2)),digits=3)
ul<  format(exp(log(3.878293) +1.96*w( 1=2)),digits=3)
cip<  data.frame(ll,ul)
# Calculation of PGOR
g<  c(28.526316, 68.645161, 5.450704, 23.123711, 15.714286, 2.990099, 3.126642
, 3.987988, 8.307692, 1.757374)
df<  length(g)-1
q2<   11.70625
k<   1-((df-2)/q2)
pg<  log(3.878293)+k(log(g)-log(3.878293))
g1<  format(exp(pg),digits=3)
g1<  c(8.65,12.31, 4.45, 7.95,6.81, 3.49, 3.56, 3.92,5.27,2.82)
wi<  c(1.0858756, 0.2918908, 1.7150532, 0.2874851, 0.1986054, 3.1277129,
3.3480683, 0.5934123, 0.7058769, 4.2951792)
ll<  format(exp(log(g1) -1.96*wi( 1=2)),digits=3) ul<  format(exp(log(g1)
+1.96*wi( 1=2)),digits=3) pci<  data.frame(ll,ul)
# Standard chisquare test
w<  c(1.0858756, 0.2918908, 1.7150532, 0.2874851, 0.1986054, 3.1277129,
3.3480683, 0.5934123, 0.7058769, 4.2951792)
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t<  c(28.526316, 68.645161, 5.450704, 23.123711, 15.714286, 2.990099, 3.126642
, 3.987988, 8.307692, 1.757374)
T<  log(t)
T2<  T*T
T3<  w%*%T
T4<  T3/sum(w)
T5<  T32
T6<  sum(w*T2)
T7<  sum(w)
q<  T6-(T5/T7)
q2<  sum(w*((T-T4)**2))
Q1<  sum(w*T2)-(T5/T7)
p<  1-pchisq(11.70625, df= 9)
# I2 for misoprostol Q<  11.70625
df<  9
I2<  (Q-df)/Q*100
if Q>df+1 then
d1<  2*df-1
q1<  2 Q
B<  0.5*(log(Q)-log(df))/(sqrt(q1)-sqrt(d1))
or
if Q<  df+1 then
p1<  3  (df   1)2
p2 <  1/2*(df-1)*(1-(1/p1))
B<  sqrt(p2)
L<  exp(0.5*log(Q/df)-1.96*B)
U<  exp(0.5*log(Q/df)+1.96*B)
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LL<  (L2   1)=L2  100
UL<  (U2   1)=U2  100
B.5 Simulation Studies
Listing B.5: R code for GORs and weights from simulated studies
set.seed(1000)
# Study 1
x1<  rmultinom(1, size = 29, prob=c(0.1099476,0.8089005,0.08115183))
x2<  rmultinom(1, size = 30, prob=c(0.1797753,0.6910112,0.1292135))
x11<  data.frame(x1,x2)
x0<  t(x11)
s<  c(29,30)
e1<  cbind(x0,s)
n11<  e1[1,4]
n21<  e1[2,4]
p11<  e1[1,1]/e1[1,4]
p12<  e1[2,1]/e1[2,4]
p13<  e1[1,3]/e1[1,4]
p21<  e1[1,2]/e1[1,4]
p22<  e1[2,2]/e1[2,4]
p23<  e1[2,3]/e1[2,4]
pc<  (p11*p22)+(p11*p23)+(p21*p23)
pd<  (p12*p21)+(p13*p12)+(p13*p22)
g1<-pc/pd
# Weight
n1<  e1[1,4]
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n2<  e1[2,4]
p11<  e1[1,1]/e1[1,4]
q11<  1-p11
p12<  e1[1,2]/e1[1,4]
q12<  1-p12
p21<  e1[2,1]/e1[2,4]
q21<  1-p21
p22<  e1[2,2]/e1[2,4]
q22<  1-p22
w11<  1/(n1*p11*q11)+1/(n1*p12*q12)+1/(n2*p21*q21)+1/(n2*p22*q22)
w1<  1/w11
# Study 2
x1<  rmultinom(1, size = 30, prob=c(0.8089005,0.1099476,0.08115183))
x2<  rmultinom(1, size = 30, prob=c(0.1797753,0.6910112,0.1292135))
# Study 3
x1<  rmultinom(1, size = 30, prob=c(0.8089005,0.08115183,0.1099476))
x2<  rmultinom(1, size = 30, prob=c(0.1797753,0.6910112,0.1292135))
# Study 4
x1<  rmultinom(1, size = 30, prob=c(0.1099476,0.8089005,0.08115183))
x2<  rmultinom(1, size = 29, prob=c(0.6910112,0.1797753,0.1292135))
# Study 5
x1<  rmultinom(1, size = 10, prob=c(0.1099476,0.8089005,0.08115183))
x2<  rmultinom(1, size = 10, prob=c(0.6910112,0.1292135,0.1797753))
# Study 6
x1<  rmultinom(1, size = 103, prob=c(0.1099476,0.8089005,0.08115183))
x2<  rmultinom(1, size = 114, prob=c(0.1797753,0.1292135,0.6910112))
x11<  data.frame(x1,x2)
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x6<  t(x11)
s<  c(103,114)
e6<  cbind(x6,s)
# Study 7
x1<  rmultinom(1, size = 73, prob=c(0.2099476,0.7089005,0.08115183))
x2<  rmultinom(1, size = 80, prob=c(0.1797753,0.6910112,0.1292135))
x11<  data.frame(x1,x2)
x7<  t(x11)
s<  c(73,80)
e7<  cbind(x7,s)
# Study 8
x1<  rmultinom(1, size = 46, prob=c(0.7089005,0.08115183,0.2099476))
x2<  rmultinom(1, size = 74, prob=c(0.1797753,0.6910112,0.1292135))
x11<  data.frame(x1,x2)
x8<  t(x11)
s<  c(46,74)
e8<  cbind(x8,s)
# Study 9
x1<  rmultinom(1, size = 32, prob=c(0.2099476,0.7089005,0.08115183))
x2<  rmultinom(1, size = 38, prob=c(0.6910112,0.1292135,0.1797753))
x11<  data.frame(x1,x2)
x9<  t(x11)
s<  c(32,38)
e9<  cbind(x9,s)
# Study 10
x1<  rmultinom(1, size = 76, prob=c(0.1099476,0.8089005,0.08115183))
x2<  rmultinom(1, size = 83, prob=c(0.1292135,0.6910112,0.1797753))
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x11<  data.frame(x1,x2)
x10<  t(x11)
s<  c(76,83)
e10<  cbind(x10,s)
# Q Statistic
w<  c(0.7578464, 2.2304833, 0.5860116, 1.3440000, 0.2526316, 2.6620506,
6.9675671, 0.7579955, 1.5819698, 2.2422012)
g<  c(1.18367347, 9.37704918, 8.62025316, 0.12962963, 0.01219512, 4.39120879,
1.45936698, 3.93109541, 0.28862974, 0.78560720)
T<  log(g)
T2<  T*T
T3<  w%*%T
T4<  T3/sum(w)
T5<  T3*T3
T6<  sum(w*T2)
T7<  sum(w)
q<  T6-(T5/T7)
q2<  sum(w*((T-T4)**2))
Q1<  sum(w*T2)-(T5/T7)
p<  1-pchisq(32.24718, df= 9)
#I2 statistic
Q<  32.24718
df<  9
I2<  (Q  df)=Q  100
if Q > df + 1 then
d1<  2  df   1
q1<  2 Q
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B<  0.5*(log(Q)-log(df))/(sqrt(q1)-sqrt(d1))
or
if Q <= df + 1
p1<  3  (df   1)2
p2<  1=2  (df   1)  (1  (1=p1))
B<  sqrt(p2)
L<  exp(0.5*log(Q/df)-1.96*B)
U<  exp(0.5*log(Q/df)+1.96*B)
LL<  (L2   1)=L2  100
UL<  (U2   1)=U2  100
# Pooling GOR
w<  c(0.7578464, 2.2304833, 0.5860116, 1.3440000, 0.2526316, 2.6620506,
6.9675671, 0.7579955, 1.5819698, 2.2422012)
g<  c(1.18367347, 9.37704918, 8.62025316, 0.12962963, 0.01219512, 4.39120879,
1.45936698, 3.93109541, 0.28862974, 0.78560720)
sn<  log(g)
t<  sum(sn*w)/sum(w)
pt<  exp(t)
# Calculation of the divergent statistic Ln
w<  c(0.7578464, 2.2304833, 0.5860116, 1.3440000, 0.2526316, 2.6620506,
6.9675671, 0.7579955, 1.5819698, 2.2422012)
sn<  c(1.18367347, 9.37704918, 8.62025316, 0.12962963, 0.01219512, 4.39120879,
1.45936698, 3.93109541, 0.28862974, 0.78560720)
wd<  diag(w)
pi<  log(sn)
s0<  rep(log( 1.482130),10)
x<  (pi-s0)
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p2<  t(x)%*%wd
ln<  p2%*%x
p3<  (t(x)%*%wd%*%x)
# Calculation of CI for individual study
wi<  c(0.7578464, 2.2304833, 0.5860116, 1.3440000, 0.2526316, 2.6620506,
6.9675671, 0.7579955, 1.5819698, 2.2422012)
g<  c(1.18367347, 9.37704918, 8.62025316, 0.12962963, 0.01219512, 4.39120879,
1.45936698, 3.93109541, 0.28862974, 0.78560720)
ll<  format(exp(log(g) -1.96*wi( 1=2)),digits=3)
ul<  format(exp(log(g) +1.96*wi( 1=2)),digits=3)
ci<  data.frame(ll,ul)
# CI for pooled GOR
w<  sum(wi)
ll<  format(exp(log(1.482130) -1.96*w( 1=2)),digits=4)
ul<  format(exp(log(1.482130) +1.96*w( 1=2)),digits=4)
cip<  data.frame(ll,ul)
# Calculation of predicted GOR
g<  c(1.18367347, 9.37704918, 8.62025316, 0.12962963, 0.01219512, 4.39120879,
1.45936698, 3.93109541, 0.28862974, 0.78560720)
df<  length(g)-1
q2<  32.24718
k<  1-((df-2)/q2)
pg<  log(1.482130)+k*(log(g)-log(1.482130))
g1<  format(exp(pg),digits=3)
g1<  c(1.2429,6.2828,5.8822,0.2200,0.0346,3.4689, 1.4643,3.1809 ,0.4117,0.9017)
wi<  c(0.7578464, 2.2304833, 0.5860116, 1.3440000, 0.2526316, 2.6620506,
6.9675671, 0.7579955, 1.5819698, 2.2422012)
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ll<  format(exp(pg -1.96*wi( 1=2)),digits=3)
ul<  format(exp(pg +1.96*wi( 1=2)),digits=3)
pci<  data.frame(ll,ul)
# Q statistic deleting 4th study
wi<  c(0.7578464, 2.2304833, 0.5860116, 0.2526316, 2.6620506, 6.9675671,
0.7579955, 1.5819698, 2.2422012)
ti<  c(1.18367347, 9.37704918, 8.62025316, 0.01219512, 4.39120879, 1.45936698,
3.93109541, 0.28862974, 0.78560720)
lt<  log(ti)
tb<  sum(lt*wi)/sum(wi)
t<  exp(tb)
q<  (wi*(lt-tb)2)
Q<  sum(wi(lt  tb)2)
# Pooling GOR deleting 4th study
w<  c(0.7578464, 2.2304833, 0.5860116, 0.2526316, 2.6620506, 6.9675671,
0.7579955, 1.5819698, 2.2422012)
g<  c(1.18367347, 9.37704918, 8.62025316, 0.01219512, 4.39120879, 1.45936698,
3.93109541, 0.28862974, 0.78560720)
sn<  log(g)
t<  sum(sn*w)/sum(w)
pt<  exp(t)
# CI of pooled
wi<  c(0.7578464, 2.2304833, 0.5860116, 0.2526316, 2.6620506, 6.9675671,
0.7579955, 1.5819698, 2.2422012)
w<  sum(wi)
ll<  format(exp(log(1.777164) -1.96*w( 1=2)),digits=3)
ul<  format(exp(log(1.777164) +1.96*w( 1=2)),digits=4)
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cip<  data.frame(ll,ul)
# Calculation of the Ln statistic deleting 4th study
w<  c(0.7578464, 2.2304833, 0.5860116, 0.2526316, 2.6620506, 6.9675671,
0.7579955, 1.5819698, 2.2422012)
sn<  c(1.18367347, 9.37704918, 8.62025316, 0.01219512, 4.39120879, 1.45936698,
3.93109541, 0.28862974, 0.78560720)
wd<  diag(w)
pi<  log(sn)
s0<  rep(log(1.777164),9)
x<  (pi-s0)
p2<  t(x)%*%wd
ln<  p2%*%x
p3<  (t(x)%*%wd%*%x)
# Calculation of predicted GOR deleting study 4
g<  c(1.18367347, 9.37704918, 8.62025316, 0.01219512, 4.39120879, 1.45936698,
3.93109541, 0.28862974, 0.78560720)
df<  length(g)-1
q2<  23.67364
k<   1-((df-2)/q2)
pg<  log(1.777164)+k*(log(g)-log(1.777164))
g1<  format(exp(pg),digits=3)
g1<  c(1.3121,6.1517,5.7771,0.0431,3.4915, 1.5341,3.2146,0.4575,0.9662)
w<  c(0.7578464, 2.2304833, 0.5860116, 0.2526316, 2.6620506, 6.9675671,
0.7579955, 1.5819698, 2.2422012)
ll<  format(exp(pg -1.96*wi( 1=2)),digits=3)
ul<  format(exp(pg +1.96*wi( 1=2)),digits=3)
pci<  data.frame(ll,ul)
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# R code for forest plot of simulation studies
x<  1.48
y<  1
plot(x,y,xlim=c(-1.5,6),ylim=c(-1,12),xaxt=\n",
yaxt=\n",frame.plot = NULL,cex=1)
segments(-0.5, 0, -0.5, 12, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(-0.5, 0, 7, 0, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(1, 0, 1, 12, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(1.48, 0, 1.48, 12, col = \black", lty = 5, lwd = par(\lwd"))
# GOR
x1<  c(0.124,11.247)
y1<  c(11,11)
lines(x1,y1,ty=\l")
x2<  c(2.524,34.835)
y2<  c(10,10)
lines(x2,y2,ty=\l")
x3<  c(0.666,111.55)
y3<  c(9,9)
lines(x3,y3,ty=\l")
x4<  c(0.023,0.703)
y4<  c(8,8)
lines(x4,y4,ty=\l")
x5<  c(0.0002,0.602)
y5<  c(7,7)
lines(x5,y5,ty=\l")
x6<  c(1.32,14.598)
y6<  c(6,6)
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lines(x6,y6,ty=\l")
x7<  c(0.694,3.066)
y7<  c(5,5)
lines(x7,y7,ty=\l")
x8<  c(0.41,37.344)
y8<  c(4,4)
lines(x8,y8,ty=\l")
x9<  c(0.06,1.371)
y9<  c(3,3)
lines(x9,y9,ty=\l")
x10<  c(0.212,2.909)
y10<  c(2,2)
lines(x10,y10,ty=\l")
x11<  c(0.95,2.313)
y11<  c(1,1)
lines(x11,y11,ty=\l")
# PGOR
x1<  c(0.13,11.81)
y1<  c(10.75,10.75)
lines(x1,y1,ty=\l",col=\black", lty=5)
x2<  c(1.69,23.34)
y2<  c(9.75,9.75)
lines(x2,y2,ty=\l",col=\black", lty=5)
x3<  c(0.454,76.12)
y3<  c(8.75,8.75)
lines(x3,y3,ty=\l",col=\black", lty=5)
x4<  c(0.04,1.19)
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y4<  c(7.75,7.75)
lines(x4,y4,ty=\l",col=\black", lty=5)
x5<  c(0.0007,1.71)
y5<  c(6.75,6.75)
lines(x5,y5,ty=\l",col=\black", lty=5)
x6<  c(1.04,11.53)
y6<  c(5.75,5.75)
lines(x6,y6,ty=\l",col=\black", lty=5)
x7<  c(0.696,3.08)
y7<  c(4.75,4.75)
lines(x7,y7,ty=\l",col=\black", lty=5)
x8<  c(0.3349,30.22)
y8<  c(3.75,3.75)
lines(x8,y8,ty=\l",col=\black", lty=5)
x9<  c(0.086,1.96)
y9<  c(2.75,2.75)
lines(x9,y9,ty=\l",col=\black", lty=5)
x10<  c(0.243,3.34)
y10<  c(1.75,1.75)
lines(x10,y10,ty=\l",col=\black", lty=5)
text(-2, 11, labels=\Study 1", pos=4,adj = c(0,0), cex = 1)
text(-2, 9.75, labels=\Study 2", pos=4,adj = c(0,0), cex = 1)
text(-2, 8.75, labels=\Study 3", pos=4,adj = c(0,0), cex = 1)
text(-2, 7.75, labels=\Study 4", pos=4,adj = c(0,0), cex = 1) text(-2, 6.75,
labels=\Study 5", pos=4,adj = c(0,0), cex = 1)
text(-2,5.75, labels=\Study 6", pos=4,adj = c(0,0), cex = 1) text(-2,4.75,
labels=\Study 7", pos=4,adj = c(0,0), cex = 1)
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text(-2, 3.75, labels=\Study 8", pos=4,adj = c(0,0), cex = 1)
text(-2,2.75, labels=\Study 9", pos=4,adj = c(0,0), cex = 1)
text(-2, 2, labels=\Study 10", pos=4,adj = c(0,0), cex = 1)
text(-2, 1, labels=\Pooled",adj = c(0,0), pos=4, cex =1)
text(1.48, 0, labels=\1.48", pos=1, adj = c(0,0),cex = 1)
text(-0.5, 0, labels=\0", pos=1, adj = c(0,0),cex = 1)
text(1, 0, labels=\1", pos=1, adj = c(0,0),cex = 1)
text(4, 0, labels=\4", pos=1, adj = c(0,0),cex = 1)
text(6, 0, labels=\6", pos=1, adj = c(0,0),cex = 1)
text(2.8, -.71, labels=\Generalised Odds Ratio (log-scale)", pos=1, adj =
c(2.50,-1),cex = 1)
points(6,0,pch=\'",cex =1)
points(4,0,pch=\'",cex =1)
# R code for rayplot for 10 simulated studies
x1<  c(0,0,0,0,0,0,0,0,0,0)
y1<  c(1.48,1.48,1.48,1.48,1.48,1.48,1.48,1.48,1.48,1.48)
plot(x,y,xlim=c(-.1,1),ylim=c(0,10), type = \n",xaxt=\n",
yaxt=\n",frame.plot = NULL,cex=1)
segments(0, 0, 1, 0, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 0, 0, 10, col = \black", lty = par(\lty"), lwd = par(\lwd"))
text(0,1.48, \1.48",adj = c(0,0), pos=2,cex=.6)
segments(0, 1.48, .45, 1.18, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 9.38, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, 0.45, 8.62, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, 0.45, 0.13, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 0.012, col = \black", lty = 1, lwd = par(\lwd"))
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segments(0, 1.48, 0.45, 4.39, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 1.46, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 3.93, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 0.29, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 1.48, .45, 0.78, col = \black", lty = 1, lwd = par(\lwd"))
segments(.45, 0, .45, 10, col = \black", lty = par(\lty"), lwd = par(\lwd"))
# Predicted OR
segments(0, 1.48, .75, 1.24, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 6.28, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 5.88, col = \black", lty = par(\lty"), lwd = par("lwd"))
segments(0, 1.48, .75, .22, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 0.0346, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 3.4689, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 1.46, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 3.18, col = \black", lty = par(\lty"), lwd = par("lwd"))
segments(0, 1.48, .75, 0.41, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 1.48, .75, 0.90, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(.75, 0, .75, 10, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 10, 1, 10, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 0, 0, 1, col = \black", lty = par(\lty"), lwd = par(\lwd"))
text(.45,1.18, \1.18 Study 1",adj = c(0,0), pos=4,cex=.6)
text(.45,9.38, \9.38 Study 2",adj = c(0,0),pos=4, cex=.6)
text(.45,8.62, \8.62 Study 3",adj = c(0,0), pos=4,cex=.6)
text(.45,0.13, \0.13 Study 4",adj = c(0,0),pos=4, cex=.6)
text(.45,0.012, \0.012 Study 5",adj = c(0,0), pos=4,cex=.6)
text(.45, 4.39, \4.39 Study 6",adj = c(0,0),pos=4, cex=.6)
text(.45,1.46, \1.46 Study 7",adj = c(0,0), pos=4,cex=.6)
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text(.45,3.93, \3.93 Study 8",adj = c(0,0), pos=4,cex=.6)
text(.45,0.29, \0.29 Study 9",adj = c(0,0), pos=4,cex=.6)
text(.45, 0.78, \0.78 Study 10",adj = c(0,0),pos=4, cex=.6)
text(.75,1.24, \1.24 Study 1",adj = c(0,0),pos=4, cex=.6)
text(.75,6.28, \6.28 Study 2",adj = c(0,0), pos=4,cex=.6)
text(.75,5.88, \5.88 Study 3",adj = c(0,0),pos=4, cex=.6)
text(.75,0.22, \0.22 Study 4",adj = c(0,0),pos=4, cex=.6)
text(.75,0.0346, \0.03 Study 5",adj = c(0,0), pos=4,cex=.6)
text(.75, 3.4689, \3.47 Study 6",adj = c(0,0),pos=4, cex=.6)
text(.75,1.46, \1.46 Study 7",adj = c(0,0),pos=4, cex=.6)
text(.75,3.18, \3.18 Study 8",adj = c(0,0),pos=4, cex=.6)
text(.75, 0.41, \0.41 Study 9",adj = c(0,0), pos=4,cex=.6)
text(.75, 0.90, \0.90 Study 10",adj = c(0,0), pos=4,cex=.6)
text(.45,0, \GOR", pos=1, cex = .6)
text(.75,0, \Predicted GOR", pos=1, cex = .6)
text(0,0, \0", pos=2, cex = .6)
text(0,10, \10", pos=2, cex = .6)
B.6 R Code for Chapter 4
Listing B.6: R code for GORs, weights, CIs for Gastric carcinoma
# Dent et al
nc<  c(3,19,22)
ca<  c(8,13,21)
e1<  cbind(nc,ca)
e<  t(e1)
n1<  e[1,3]
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n2<  e[2,3]
p11<  e[1,1]/e[1,3]
p12<  e[2,1]/e[2,3]
p21<  e[1,2]/e[1,3]
p22<  e[2,2]/e[2,3]
pc<  (p11*p22)
pd<  (p12*p21)
g1<  pc/pd
v1<  (p11*((p22)2))+(p21*((-g1*p12)2))
v2<  ((-g1*(p21))**2)*(p12)+((p11)**2)*(p22)
vg1<  v1/((n1)*(pd**2))+v2/((n2)*(pd**2))
sevg1<  sqrt(vg1)
ll2<  g1*exp(-1.96*sevg1/g1)
ul2<  g1*exp(1.96*sevg1/g1)
ci21<  c(ll2,ul2)
# Robertson et al
nc<  c(0.5,25.5,26)
ca<  c(24.5,5.5,30)
# Bonenkamp et al
nc<  c(128,385,513)
ca<  c(183,300,483)
# Cuschieri et al
nc<  c(55,145,200)
ca<  c(92,108,200)
# Degiuli et al
nc<  c(8,68,76)
ca<  c(14,72,86)
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# Chew et al
nc<  c(8,102,110)
ca<  c(19,92,111)
# R code for weights
# Dent et al
x11<  f11
x12<  f12
x21<  f21
x22<  f22
n1<  rst row total
n2<  second row total
p11<  x11/n1
q11<  1-p11
p12<  x12/n1
q12<  1-p12
p21<  x21/n2
q21<  1-p21
p22<  x22/n2
q22<  1-p22
w1i<  1/(n1*p11*q11)+1/(n2*p21*q21)
wi<  1/w1i; i= 1; 2; : : : ; 6.
# Pooling logGOR
g2<  c(0.256578947, 0.004401761, 0.545028742, 0.445277361, 0.605042017,
0.379772962)
g<  log(g2)
wi<  c(1.7010043, 0.4421159, 52.0624086, 22.1203730, 4.4439834, 5.0427355)
t<  sum(g*wi)/sum(wi)
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pt<  exp(t)
# Calculation of ci for individual GOR for gastric carcinoma
wi<  c(1.7010043, 0.4421159, 52.0624086, 22.1203730, 4.4439834, 5.0427355)
g<  c(0.256578947, 0.004401761, 0.545028742, 0.445277361, 0.605042017,
0.379772962)
ll<  format(exp(log(g) -1.96*wia( 1=2)),digits=2)
ul<  format(exp(log(g) +1.96*wi( 1=2)),digits=2)
ci<  data.frame(ll,ul)
# CI for pooled
w<  sum(wi) ll<  format(exp(log(0.4893854) -1.96*w( 1=2)),digits=4)
ul<  format(exp(log(0.4893854) +1.96*w( 1=2)),digits=4)
ci<  data.frame(ll,ul)
# Ln Statistic
sn<  c(0.2566, 0.0044, 0.545, 0.4453, 0.6050, 0.3798)
w<  c(1.7010043, 0.4421159, 52.0624086, 22.1203730, 4.4439834, 5.0427355)
wd<  diag(w)
pi<  log(sn)
s0<  rep(log(0.4893854),6)
x<  (pi-s0)
p2<  t(x)% %wd
ln<  p2% %x
# Calculation of PGOR g<  c(0.256578947, 0.004401761, 0.545028742,
0.445277361, 0.605042017, 0.379772962)
df<  length(g)-1
w<  c(1.7010043, 0.4421159, 52.0624086, 22.1203730, 4.4439834, 5.0427355)
q2<  11.85
k<  1-((df-2)/q2) pg<  log(0:4893854) + k  (log(g)  log(0:4893854))
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g1<  exp(pg) # CI for PGOR
wi<  c(1.7010043, 0.4421159, 52.0624086, 22.1203730, 4.4439834, 5.0427355)
ll<  format(exp(pg-1.96*wi( 1=2)),digits=4)
ul<  format(exp(pg+1.96*wi( 1=2)),digits=4)
cip<  data.frame(ll,ul)
# ray plot of gastric carcinoma with 6 studies x1<  c(0,0,0,0,0,0)
y1<  c(0.4893854,0.4893854,0.4893854,0.4893854,0.4893854,0.4893854)
plot(x,y,xlim=c(-.1,1),ylim=c(-.10,1), type = \n",xaxt=\n",
yaxt=\n",
frame.plot = NULL,cex=1)
segments(0, 0, 1, 0, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 0, 0, 1, col = \black", lty = par(\lty"), lwd = par(\lwd"))
text(0,0.4893854, \0.49",adj = c(0,0), pos=2,cex=.6)
segments(0, 0.4893854, .45, 0.26, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 0.4893854, .45, 0.004, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 0.4893854, 0.45, 0.54, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 0.4893854, 0.45, 0.44, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 0.4893854, .45, 0.60, col = \black", lty = 1, lwd = par(\lwd"))
segments(0, 0.4893854, 0.45, 0.38, col = \black", lty = 1, lwd = par(\lwd"))
segments(.45, 0, .45, 1, col = \black", lty = par(\lty"), lwd = par(\lwd"))
# PGOR
segments(0, 0.4893854, .75, 0.30, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
segments(0, 0.4893854, .75, 0.01, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
segments(0, 0.4893854, .75, 0.53, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
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segments(0, 0.4893854, .75, 0.46, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
segments(0, 0.4893854, .75, 0.57, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
segments(0,0.4893854, .75, 0.40, col = \black", lty = par(\lty"), lwd =
par(\lwd"))
segments(.75, 0, .75, 1, col = \black", lty = par(\lty"), lwd = par("lwd"))
segments(0, 1, 1, 1, col = "black", lty = par("lty"), lwd = par(\lwd"))
segments(0, 0, 0, 1, col = \black", lty = par(\lty"), lwd = par(\lwd"))
text(.45,0.26, \0.26 Dent",adj = c(0,0), pos=4,cex=.6)
text(.45,0.02, \0.004 Robertson",adj = c(0,0),pos=4, cex=.6)
text(.45, 0.54, \0.54 Bonenkamp",adj = c(0,0), pos=4,cex=.6)
text(.45,0.44, \0.44 Cuschieri",adj = c(0,0),pos=4, cex=.6)
text(.45,0.60,\0.60 Degiuli",adj = c(0,0), pos=4,cex=.6)
text(.45, 0.38, \0.38 Chew- Wun",adj = c(0,0),pos=4, cex=.6)
text(.75,0.30, \0.30 Dent",adj = c(0,0),pos=4, cex=.6)
text(.75,0.03, \0.01 Robertson",adj = c(0,0), pos=4,cex=.6)
text(.75,0.53, \0.53 Bonenkamp",adj = c(0,0),pos=4, cex=.6)
text(.75,0.46, \0.46 Cuschieri",adj = c(0,0),pos=4, cex=.6)
text(.75,0.57, \0.57 Degiuli",adj = c(0,0), pos=4,cex=.6)
text(.75, 0.40, \0.40 Chew- Wun",adj = c(0,0),pos=4, cex=.6)
text(.45,0, \GOR", pos=1, cex = .6)
text(.75,0, \PGOR", pos=1, cex = .6)
text(0,0, \0", pos=2, cex = .6)
text(0,1, \1", pos=2, cex = .6)
# Forest plot gastric carcinoma
x<  0.4893854
APPENDIX B. 138
y<  1
plot(x,y,xlim=c(-.5,1.6),ylim=c(-1,8),xaxt=\n",
yaxt=\n",frame.plot = NULL,cex=1)
segments(0, 0, 0, 8, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0, 0, 1.6, 0, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(1, 0, 1, 8, col = \black", lty = par(\lty"), lwd = par(\lwd"))
segments(0.4893854, 0, 0.4893854, 8, col = \black", lty = 5, lwd = par(\lwd"))
# GOR
x5<  c(0.057,1.1532)
y5<  c(7,7)
lines(x5,y5,ty=\l")
x6<  c(0.00023,0.083)
y6<  c(6,6)
lines(x6,y6,ty=\l")
x7<  c(0.4153,0.7151)
y7<  c(5,5)
lines(x7,y7,ty=\l")
x8<  c(0.2935,0.6755)
y8<  c(4,4)
lines(x8,y8,ty=\l")
x9<  c(0.2387,1.533)
y9<  c(3,3)
lines(x9,y9,ty=\l")
x10<  c(0.1586,0.9091)
y10<-c(2,2)
lines(x10,y10,ty=\l")
x11<  c(0.3961, 0.6047)
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y11<  c(1,1)
lines(x11,y11,ty=\l")
text(0, 7, labels=\Dent", pos=2,adj = c(0,0), cex = .6)
text(0, 6, labels=\Robertson", pos=2,adj = c(0,0), cex = .6)
text(0, 5, labels=\Bonenkamp", pos=2,adj = c(0,0), cex = .6)
text(0, 4, labels=\Cuschieri", pos=2,adj = c(0,0), cex = .6)
text(0, 3, labels=\Degiuili", pos=2,adj = c(0,0), cex = .6)
text(0, 2, labels=\Chew-Wun", pos=2,adj = c(0,0), cex = .6)
text(0, 1, labels=\MA",adj = c(0,0), pos=2, cex =.6)
# PGOR
x5<  c(0.067229, 1.3579)
y5<  c(6.75,6.75)
lines(x5,y5,ty=\l",col=\black",lty=5)
x6<  c(0.000761, 0.2766)
y6<  c(5.75,5.75)
lines(x6,y6,ty=\l",col=\black",lty=5)
x7<  c(0.404210, 0.6959)
y7<  c(4.75,4.75)
lines(x7,y7,ty=\l",col=\black",lty=5)
x8<  c(0.300628, 0.6918)
y8<  c(3.75,3.75)
lines(x8,y8,ty=\l",col=\black",lty=5)
x9<  c(0.226293, 1.4529)
y9<  c(2.75,2.75)
lines(x9,y9,ty=\l",col=\black",lty=5)
x10<  c(0.169178, 0.9693)
y10<  c(1.75,1.75)
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lines(x10,y10,ty=\l",col=\black",lty=5)
text(0.4893854, 0, labels=\0.49", pos=1, adj = c(0,0),cex = .7)
text(0, 0, labels=\0", pos=1, adj = c(0,0),cex = .7)
text(1, 0, labels=\1", pos=1, adj = c(0,0),cex = .7)
text(6, 0, labels=\6", pos=1, adj = c(0,0),cex = .7)
text(.8, -.71, labels="GOR(log-scale)", pos=1, adj = c(2.50,-1),cex = .7)
text(-0.25, 8, labels="(b)",adj = c(0,0), pos=2, cex =.6)
# Sample size weighting for gastric carcinoma
# Dent et al
cl<  c(8,13,21)
tr<  c(3,19,22)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
or1<  p1/q1
ga1<  (p1-q1)/(p1+q1)
seg1<  0.249#From SPSS
#seg=se(gamma)
selg1<  (2*seg1)/((1-ga1)2)
# selg<  SE(log ORG)
ci1<  c(or1*exp((-3.92*seg1)/(1-(ga1)2)),or1*exp((3.92*seg1)/(1-(ga1)2)))
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# Robertson et al
cl<  c(24.5,5.5,30)
tr<  c(0.5,25.5,26)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
or2<  p1/q1
ga2<  (p1-q1)/(p1+q1)
seg2<  0.020 # From SPSS
selg2<  (2*seg2)/((1-ga2)2)
ci2<  c(or2*exp((-3.92*seg2)/(1-(ga2)2)),or2*exp((3.92*seg2)/(1-(ga2)2)))
# Bonenkamp et al
tr<  c(128,385,513)
cl<  c(183,300,483)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
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or3<  p1/q1
ga3<  (p1-q1)/(p1+q1)
seg3<   0.063
selg3<  (2*seg3)/((1-ga3)2)
ci3<  c(or3*exp((-3.92*seg3)/(1-(ga3)2)),or3*exp((3.92*seg3)/(1-(ga3)2)))
# Cuschiei et al
cl<  c(92,108,200)
tr<  c(55,145,200)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
or4<  p1/q1
ga4<  (p1-q1)/(p1+q1)
seg4<   0.091
selg4<  (2*seg4)/((1-ga4)2)
ci4<  c(or4*exp((-3.92*seg4)/(1-(ga4)2)),or4*exp((3.92*seg4)/(1-(ga4)2)))
# Degiuli et al
cl<  c(14,72,86)
tr<  c(8,68,76)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
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n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
or5<  p1/q1
ga5<  (p1-q1)/(p1+q1) seg5<   0.223 selg5<  (2*seg5)/((1-ga5)2)
ci5<  c(or5*exp((-3.92*seg5)/(1-(ga5)2)),or5*exp((3.92*seg5)/(1-(ga5)2)))
# Chew et al
cl<  c(19,92,111)
tr<  c(8,102,110)
e1<  cbind(tr,cl)
e<  t(e1)
n11<  e[1,1]
n12<  e[1,2]
n21<  e[2,1]
n22<  e[2,2]
p1<  n11*n22
q1<  n12*(n21)
or6<  p1/q1
ga6<  (p1-q1)/(p1+q1)
seg6<   0.178
selg6<  (2*seg6)/((1-ga6)2)
ci6<  c(or6*exp((-3.92*seg6)/(1-(ga6)2)),or6*exp((3.92*seg6)/(1-(ga6)2)))
# Sample size weights
#n1<  n11+n21
#n2<  n12+n22
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#n3<  n13+n23
# Dent et al
n1<  11
n2<  32
ga<  -0.592
seg<  0.249
se2<  seg2
tn1<  n1*n2/(n1+n2)
# Robertson et al
n1<  24
n2<  30
tn2<  n1*n2/(n1+n2)
# Bonenkamp et al
n1<  311
n2<  685
tn3<  n1*n2/(n1+n2)
# Cuschieri et al
n1<  147
n2<  253
tn4<  n1*n2/(n1+n2)
# Degiuli et al
n1<  22
n2<  140
tn5<  n1*n2/(n1+n2)
# Chew et al
n1<  27
n2<  194
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tn6<  n1*n2/(n1+n2)
tn<  c(tn1,tn2,tn3,tn4,tn5,tn6)
tn<  c(8.186047, 13.333333, 213.890562, 92.977500, 19.012346, 23.701357)
# Pooling by Edwardes
ga<  c(-0.591623, -0.9912351, -0.2944743, -0.3838174, -0.246073, -0.449513)
seg<  c(0.249, 0.020, 0.063, 0.091, 0.223,0.178)
se2<  seg2
tn<  c(8.186047, 13.333333, 213.890562, 92.977500, 19.012346, 23.701357)
tn2<  tn2
gb<  sum(tn*ga)/sum(tn)
ORb<  (1+gb)/(1-gb)
segb<  sqrt(sum(tn2*se2))/sum(tn)
cip<  c(ORb*exp((-3.92*segb)/(1-(gb)2)),ORb*exp((3.92*segb)/(1-(gb)2)))
B.7 R Code for Chapter 5
# R code for continuous outcomes from simulated data
set.seed(12100)
x1<  rmultinom(1, size = 20, prob=c(0.1,0.15,0.45,0.3))
x2<  rmultinom(1, size = 22, prob=c(0.0909091, 0.1363636, 0.4545455,
0.3181818))
x3<  rmultinom(1, size = 33, prob=c(0.03030303, 0.1818182, 0.4242424
,0.3636364))
x4<  rmultinom(1, size = 21, prob=c(0.03, 0.04761905, 0.3285714 , 0.5938095))
x11<  data.frame(x1,x2,x3,x4)
x0<  t(x11)
s<  c(20,22,33,21)
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e<  cbind(x0,s)
p11<  e[1,1]/e[1,5]
p12<  e[1,2]/e[1,5]
p13<  e[1,3]/e[1,5]
p14<  e[1,4]/e[1,5]
p21<  e[2,1]/e[2,5]
p22<  e[2,2]/e[2,5]
p23<  e[2,3]/e[2,5]
p24<  e[2,4]/e[2,5]
p31<  e[3,1]/e[3,5]
p32<  e[3,2]/e[3,5]
p33<  e[3,3]/e[3,5]
p34<  e[3,4]/e[3,5]
p41<  e[4,1]/e[4,5]
p42<  e[4,2]/e[4,5]
p43<  e[4,3]/e[4,5]
p44<  e[4,4]/e[4,5]
pc<  p11*(p22+p23+p24+p32+p33+p34+p42+p43+p44)+
p12*(p23+p24+p33+p34+p43+p44)+p21*(p32+p33+p34+p42+p43+p44)+
p22*(p33+p34+p43+p44)+p23*(p34+p44)+p31*(p42+p43+p44)+
p32*(p43+p44)+p33*p44
pd<  p12*(p21+p31+p41)+p13*(p21+p22+p31+p32+p41+p42)+
p14*(p21+p22+p23+p31+p32+p33+p41+p42+p43)+
p22*(p31+p41)+p23*(p31+p32+p41+p42)+p24*(p31+p32+p33+p41+p42+p43)+
p32*p41+p33*(p41+p42)+p34*(p41+p42+p43)
g1<  pc/pd
# weight 1
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n1<  e[1,5]
n2<  e[2,5]
n3<  e[3,5]
n4<  e[4,5]
p11<  e[1,1]/e[1,5]
q11<  1-p11
p12<  e[1,2]/e[1,5]
q12<  1-p12
p13<  e[1,3]/e[1,5]
q13<  1-p13
p21<  e[2,1]/e[2,5]
q21<  1-p21
p22<  e[2,2]/e[2,5]
q22<  1-p22
p23<  e[2,3]/e[2,5]
q23<  1-p23
p31<  e[3,1]/e[3,5]
q31<  1-p31
p32<  e[3,2]/e[3,5]
q32<  1-p32
p33<  e[3,3]/e[3,5]
q33<  1-p33
p41<  e[4,1]/e[4,5]
q41<  1-p41
p42<  e[4,2]/e[4,5]
q42<  1-p42
p43<  e[4,3]/e[4,5]
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q43<  1-p43
w11<  (1/(n1*p11*q11)+1/(n2*p21*q21)+1/(n3*p31*q31)
+1/(n4*p41*q41)
+1/(n1*p12*q12)+1/(n2*p22*q22)+1/(n3*p32*q32)+1/(n4*p42*q42)
+1/(n1*p13*q13)+1/(n2*p23*q23)+1/(n3*p33*q33)+1/(n4*p43*q43))
w1<  1/w11
# Study 2
set.seed(12100)
x1<  rmultinom(1, size = 20, prob=c(0.15,0.15,0.45,0.3))
x2<  rmultinom(1, size = 22, prob=c(0.0909091, 0.1863636, 0.4045455,
0.3181818))
x3<  rmultinom(1, size = 33, prob=c(0.03030303, 0.21818182, 0.4242424
,0.336364))
x4<  rmultinom(1, size = 21, prob=c(0.02, 0.09761905, 0.285714 , 0.6038095))
x11<  data.frame(x1,x2,x3,x4)
x0<  t(x11)
s<  c(20,22,33,21)
e<  cbind(x0,s)
# Study 3
set.seed(12100)
x1<  rmultinom(1, size = 20, prob=c(0.1,0.20,0.4,0.3))
x2<  rmultinom(1, size = 22, prob=c(0.0909091, 0.1063636, 0.4845455,
0.3181818))
x3<  rmultinom(1, size = 33, prob=c(0.03030303, 0.21818182, 0.4542424
,0.306364))
x4<  rmultinom(1, size = 21, prob=c(0.01, 0.14761905, 0.245714 , 0.6038095))
x11<  data.frame(x1,x2,x3,x4)
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x0<  t(x11)
s<  c(20,22,33,21)
e<  cbind(x0,s)
# Study 4
set.seed(12100)
x1<  rmultinom(1, size = 20, prob=c(0.07,0.25,0.33,0.35))
x2<  rmultinom(1, size = 22, prob=c(0.0909091, 0.1463636, 0.4045455,
0.3581818))
x3<  rmultinom(1, size = 33, prob=c(0.05030303, 0.26818182, 0.4342424
,0.256364))
x4<  rmultinom(1, size = 21, prob=c(0.01, 0.1761905, 0.355714 , 0.5838095))
x11<  data.frame(x1,x2,x3,x4)
x0<  t(x11)
s<  c(20,22,33,21)
e<  cbind(x0,s)
# Study 5
set.seed(12100)
x1<  rmultinom(1, size = 20, prob=c(0.10,0.15,0.3,0.45))
x2<  rmultinom(1, size = 22, prob=c(0.1109091, 0.1863636, 0.3445455,
0.3581818))
x3<  rmultinom(1, size = 33, prob=c(0.03030303, 0.20818182, 0.3942424
,0.376364))
x4<  rmultinom(1, size = 21, prob=c(0.00, 0.1761905, 0.285714 , 0.6838095))
x11<  data.frame(x1,x2,x3,x4)
x0<  t(x11)
s<  c(20,22,33,21)
e<  cbind(x0,s)
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g<  c(g1,g2,g3,g4,g5)
w<  c(w1,w2,w3,w4,w5)
# Pooling log GOR
g<  c(1.344747, 1.355527, 1.240727, 1.391849, 1.118055)
g1<  log(g)
w<  c(0.1731767, 0.1953294, 0.1766055, 0.1851793, 0.1206612)
t<  sum(g1*w)/sum(w)
T<  exp(t)
# calculation of ci for individual GOR
g<  c(1.344747, 1.355527, 1.240727, 1.391849, 1.118055)
wi<  c(0.1731767, 0.1953294, 0.1766055, 0.1851793, 0.1206612)
ll<  format(exp(log(g) -1.96*wi(   1=2)),digits=5)
ul<  format(exp(log(g) +1.96*wi(   1=2)),digits=5)
ci<  data.frame(ll,ul)
# CI for pooled GOR
w<  sum(wi)
ll<  format(exp(log(1.303739) -1.96*w(   1=2)),digits=4)
ul<  format(exp(log(1.303739) +1.96*w(   1=2)),digits=4)
cip<  data.frame(ll,ul)
# Q value
g<  c(1.344747, 1.355527, 1.240727, 1.391849, 1.118055)
w<  c(0.1731767, 0.1953294, 0.1766055, 0.1851793, 0.1206612)
T<  log(g)
T2<  T*T
T3<  w%*%T
T4<  T3/sum(w)
T5<  T32
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T6<  sum(w*T2)
T7<  sum(w)
q<  T6  (T5=T7)
q2<  sum(w*((T-T4)**2))
Q1<  sum(w*T2)-(T5/T7)
p<  1-pchisq(0.004530595, df= 4)
# I2
Q<  0.004530595
df<  4
I2<  (Q-df)/Q*100
#if Q>df+1 then
# d1<  2*df-1
#q1<  2*Q
#B<  0.5*(log(Q)-log(df))/(sqrt(q1)-sqrt(d1))
#or if Q<=df+1, compute
p1<  3*(df-1)2
p2<  1/2*(df-1)*(1-(1/p1))
B<  sqrt(p2)
L<  exp(0.5*log(Q/df)-1.96*B)
U<  exp(0.5*log(Q/df)+1.96*B)
LL<  (L2-1)/L2  100
UL<  (U2-1)/U2  100
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